

Prof. Dr. Onur Başer

ADRES

211 N. 4th Avenue
Suite 2B
Ann Arbor, MI, 48104
(734) 222-5426
obaser@statinmed.com

EĞİTİM

2002 Doktora, Michigan State University, Ekonomi [Danışman: Prof. Dr. Jeffrey M. Wooldridge]
2001 Yüksek Lisans, Michigan State University, İstatistik
1998 Yüksek Lisans, Michigan State University, Ekonomi
1996 Yüksek Lisans, Orta Doğu Teknik Üniversitesi, Türkiye, Ekonomi
1994 Lisans, Ortadoğu Teknik Üniversitesi, Türkiye, Ekonomi

SERTİFİKA VE LİSANSLAR

2005 Sağlık Sonuç Araştırmalarında Ölçüm, Tasarım ve Analiz Yöntemleri,
Harvard Üniversitesi, Halk Sağlığı

PROFESYONEL DENEYİM

07/2015 – *Baş Bilim Adamı (Chief Scientific Officer), STATinMED Araştırma, New York, NY*
07/2015 – *Doçent, Cerrahi, Columbia University, New York, NY*
06/2014 – *Profesör, Ekonomi, MEF Üniversitesi, İstanbul, Türkiye*
02/2013 – *Baş Editör, Journal of Health Economics and Outcomes Research (JHEOR), Ann Arbor, MI*
07/2011 – *Adjunct Fakülte Üyesi, Dahili Tıp, The University of Michigan, Ann Arbor MI*
01/2008 – *Danışma Kurulu Üyesi, Profesyonel Gelişim, City University of New York, New York, NY*
04/2007 – 07/2015 *Başkan ve Yönetim Kurulu Üyesi (CEO), STATinMED Araştırma, Ann Arbor, MI*
12/2013 – 06/2014 *Araştırma Komitesi Eş Başkanı, 19th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ*
12/2012 – 06/2013 *Araştırma Komitesi Eş Başkanı, 18th Annual International Meeting, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Lawrenceville, NJ*
08/2006 – 09/2010 *Doçent, Cerrahi, The University of Michigan, Ann Arbor MI*

PROFESYONEL DENEYİM – Devamı

08/2002 – 04/2007 *Baş Sağlık Ekonomisti, Araştırma ve Politika Geliştirme, Sonuç Araştırmaları ve Ekonometri, Thomson Health Care, Ann Arbor, MI*

Onur Başer
Sayfa 2

- 04/2000 – 08/2002 *Araştırma Görevlisi, Tıp Merkezi, Michigan State University, East Lansing, MI*
- 07/1998 – 05/2002 *Öğretim Asistanı (Lisans Düzeyinde), Matematik ve Ekonomi Bölümü, Michigan State University, East Lansing, MI*
- 08/1998 – 05/2002 *Matematik Program Geliştirici, Destek Hizmetler Ofisi, MSU, East Lansing, MI*
- 09/1997 – 08/1998 *Veri Tabanı Yönetim Uzmanı, State of Michigan, Michigan Economics Development Corporation, Lansing, MI*
- 05/1994 – 06/1996 *Öğretim Asistanı (Lisans Düzeyinde), Ekonomi, ODTU, Ankara, Türkiye*
- 05/1995 – 04/1996 *Denetçi, OYAK, Ankara, Türkiye*

DİĞER DENEYİMLER

- 08/2010 - *Eğitmen, (Konferans-Öncesi Kısa Kurs) “Retrospective Database Analysis” International Society of Pharmaceutical and Outcomes Research (ISPOR) - Prague*
- 08/2008 - *Profesyonel Gelişim Danışma Kurulu Üyesi, City University of New York*
- 08/2008 - *Eğitmen, (Konferans-Öncesi Kısa Kurs), “Retrospective Analysis of Medical Data”, International Society of Pharmaceutical and Outcomes Research (ISPOR) - USA*
- 08/2007 - 07/2008 *Bilirkişi, Amgen vs. Ortho Biotec (Antitröst Davası)*

ULUSLARARASI HAKEMLİ DERGİLERDE YAYINLANAN MAKALELER

1. Xie L, Vo L, Keshishian A, Price K, Singh P, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: an early view. *J Med Econ.* 2016 Apr 24:1-8. [Yayınlanmak üzere kabul edildi]
2. Baser O, Wang L, Maguire J. Creating national weights for a patient-level longitudinal database. *JHEOR.* 2016;4(1):80-9.
3. Nelson WW, Milentijevic D, Wang L, Baser O, Damaraju CV, Schein JR. Patterns of international normalized ratio values among new warfarin patients with non-valvular atrial fibrillation. *Blood Coag Fibrinolysis.* 2016 Feb 15. [Yayınlanmak üzere kabul edildi]
4. Fox K, Wang L, Gandra S, Quek R, Li L, Baser O. Clinical and economic burden associated with cardiovascular events among patients with hyperlipidemia: a retrospective cohort study. *BMC Cardiovasc Disord.* 2016;16(1):13. DOI: 10.1186/s12872-016-0190-x.
5. Baser O, Altınbas A, Baser E, Karıburcu F. Economic burden and complications of treated and untreated hepatitis C virus patients in Turkey. *Value Health Regional Issues.* 2015;7C:42-8.
6. Keshishian A, Wang Y, Xie L, Baser O. The economic impact of symptomatic menopause among low-socioeconomic women in the United States. *Expert Rev Pharmacoecon Outcomes Res.* 2016;16(2):305-13.

7. Dasta J, Waikar SS, Xie L, Boklage S, Baser O, et al. Patterns of treatment and correction of hyponatremia in intensive care-unit patients. *J Crit Care.* 2015;30(5):1072-9.
8. Zedler B, Xie L, Wang L, Joyce A, Vick C, Brigham J, Kariburyo MF, Baser O, Murrelle L. Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans' Health Administration patients. *Pain Med.* 2015;16(8):1566-79.
9. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range international normalized ratio values and healthcare cost among new warfarin patients with non-valvular atrial fibrillation. *J Med Econ.* 2015;18(5):333-40.
10. Baser O, Ganguli A, Roy S, Xie L, Cifaldi M. Impact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritis. *Clin Ther.* 2015;37(7):1454-65.
11. Wang L, Baser O, Kutikova L, Page JH, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. *Support Care Cancer.* 2015;23(11):3131-40.
12. Zhong L, Chung KC, Baser O, Fox DA, Yuce H, Waljee JF. Variation in rheumatoid hand and wrist surgery among Medicare beneficiaries: A population-based cohort study. *J Rheumatol.* 2015;42(3):429-36.
13. Baser O, Xie L, Pesa J, Durkin M. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. *J Med Econ.* 2015;18(5):357-65.
14. Waljee J, Zhong L, Baser O, Fox DA, Chung KC, Yuce H. The incidence of upper and lower extremity surgery for rheumatoid arthritis: A national, population-based longitudinal cohort study. *J Bone Joint Surg.* 2015;97(5):403-10.
15. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Warfarin discontinuation in patients with unprovoked venous thromboembolism: A large U.S. insurance database analysis. *Am J Ther.* 2015 July 24. [Epub ahead of print]
16. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. *Int J Clin Pharm.* 2015;37(1):53-9.
17. Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data. *Diabetes Obes Metab.* 2015;17(3):245-53.
18. Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, Simpson KN. HIV economic burden of illness in the Veterans Health Administration population. *AIDS Care.* 2015;27(1):123-31.
19. Xie L, Frech-Tamas F, Marrett E, Baser O. A medication and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. *Curr Med Res Opin.* 2014;30(12):2415-22.
20. Bui CN, Wang L, Baser O. Resource utilization and use of life-extending therapies and corticosteroids in prostate cancer patients with corticosteroid-sensitive comorbidities. *Curr Med Res Opin.* 2014;30(11):2355-64.

21. Dalal MR, Xie L, Baser O, DiGenio A. Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin: Outcomes in a community setting. *Endocr Pract.* 2015;21(1):68-76.
22. Wang L, Barron R, Baser O, Langeberg WJ, Dale DC. Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration. *Value Health.* 2014;17(6):739-43.
23. Lo Re V 3rd, Wang L, Devine S, Baser O, Olufade T. Hepatic decompensation in patients with HIV/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy. *Clin Infect Dis.* 2014;59(7):1027-31.
24. Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J. Much ado about nothing? A real-world study of patients with type 2 diabetes switching basal insulin analogs. *Adv Ther.* 2014;31(5):539-60.
25. Zedler B, Xie L, Wang L, Joyce A, Vick C, Kariburyo F, Rajan P, Baser O, Murrelle L. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. *Pain Med.* 2014;15(11):1911-29.
26. Levin P, Lin J, Wei W, Vlajnic A, Pan C, Xie L, Baser O. Initiating injectable therapy in US managed care patients with diabetes. *Am J Pharm Benefits.* 2014;6(4):e93-e102.
27. Altinbas A, Baser E, Burkan A, Ertugay E, Kariburyo MF, Baser O. Retrospective analysis of total direct medical costs of hepatitis B patients with oral antiviral versus pegylated interferon therapy in Turkey. *J Viral Hepat.* 2014;21(11):794-801.
28. Xie L, Zhou S, Pinsky BW, Buysman EK, Baser O. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: A claims database analysis. *Diabetes Technol Ther.* 2014;16(9):567-75.
29. Levin PA, Wei W, Zhou S, Xie L, Baser O. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes. *J Manag Care Pharm.* 2014;20(5):501-12.
30. Miao R, Wei W, Lin J, Xie L, Baser O. Does device make any difference? A real-world retrospective study of insulin glargine treatment among elderly patients with type 2 diabetes. *J Diabetes Sci Technol.* 2014;8(1):150-8.
31. Wei W, Pan C, Xie L, Baser O. Real-world insulin treatment persistence among patients with type 2 diabetes: Measures, predictors and outcomes. *Endocr Pract.* 2014;20(1):52-61.
32. Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. *Clinicoecon Outcomes Res.* 2013;5:497-505.
33. Miao R, Wei W, Baser O, Xie L. Real world outcomes of adding rapid-acting insulin versus switching to analog premix insulin among US patients with type 2 diabetes treated with insulin glargine. *Patient Prefer Adherence.* 2013;7:951-60.
34. Xie L, Wei W, Pan C, Baser O. Real-world rates, predictors and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: Results of a pooled analysis of six retrospective observational studies. *J Med Econ.* 2013;16(9):1137-45.
35. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Coronary angiography utilization and costs for coronary artery bypass graft surgery in Turkey. *Cardiol Ther.* 2013;2:151-63.

36. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Direct medical costs associated with rheumatoid arthritis in Turkey: Analysis from national claims data. *Rheumatol Int.* 2013;33(10):2577-84.
37. Baser O, Xie L, Mardekian J, Schaaf D, Wang L, Joshi AV. Prevalence of diagnosed opioid abuse and its economic burden in the Veterans Health Administration. *Pain Pract.* 2014;14(5):437-45.
38. Wang L, Wei W, Miao R, Xie L, Baser O. Real-world outcomes of US employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn insulin: A comparative retrospective database study. *BMJ Open.* 2013;3(4):1-9.
39. Xie L, Joshi AV, Schaaf D, Mardekian J, Harnett J, Shah ND, Baser O. Differences in healthcare utilization and associated costs between patients prescribed versus not prescribed opioids during an inpatient or emergency department visit. *Pain Pract.* 2014;14(5):446-56.
40. Wang L, Fritschel E, Baser O. Economic and clinical impact of stroke and warfarin use for patients with non-valvular atrial fibrillation. *JHEOR.* 2013;1(1):42-53.
41. Baser O, Baser E, Altinbas A, Burkan A. Severity index for rheumatoid arthritis and its association with health care costs and biologic therapy use in Turkey. *Health Econ Rev.* 2013;3(5):1-7.
42. Wang L, Lewis-Beck C, Fritschel E, Baser E, Baser O. Applied comparison of meta-analysis techniques. *JHEOR.* 2013;1(1):14-22.
43. Baser O. Generalized propensity score matching with multilevel treatment options. *JHEOR.* 2013;1(1):1-13.
44. Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus. *Diabetes Technol Ther.* 2013;15(3):1-7.
45. Baser O, Xie L, Du J. Application of probabilistic linkage: Compare health care costs among menopausal women with different symptoms by linking women's registry and claims data. *Int J Stats Med Res.* 2013;2:34-9.
46. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Health care costs associated with ankylosing spondylitis in Turkey: Analysis from nationwide real-world data. *Int J Rheumatol.* 2013;2013:1-7.
47. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate to severe psoriasis using structural equation modeling. *Patient Prefer Adher.* 2013;7:199-205.
48. Baser O, Verpillat P, Gabriel S, Wang L. Prevalence, incidence, and outcomes of critical limb ischemia in the U.S. Medicare population. *Vasc Dis Man.* 2013;10(2):1-9.
49. Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients. *Am J Therapeut.* 2013;20(2):132-42.
50. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. High cost patients for cardiac surgery and hospital quality in Turkey. *Health Policy.* 2013;109(2):143-9.
51. Baser O, Wei W, Henk HJ, Teitelbaum A, Xie L. Burden of early stage triple-negative breast cancer in a U.S. managed care plan. *Health Outcomes Res Med.* 2012;3(2):e57-e65.

52. Baser O, Wang L, Sengupta N, Dysinger AH. Thromboembolism prophylaxis in medical inpatients: Effect on outcomes and costs. *Am J Man Care*. 2012;18(6):294-302.
53. Baser O, Du J, Xie L, Wang H, Dysinger AH, Wang L. Derivation of severity index for rheumatoid arthritis and its association with healthcare outcomes. *J Med Econ*. 2012;15(5):918-24.
54. Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-TNF therapy. *Arthritis Care Res*. 2012;64(9):1282-91.
55. Baser O, Wei W, Henk H, Teitelbaum A, Xie L. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry. *Curr Med Res Opin*. 2012;28(3):419-28.
56. Baser O, Wei W, Xie L, Henk HJ, Teitelbaum A. Retrospective study of patients with metastatic triple-negative breast cancer: survival, health care utilization, and cost. *Commun Oncol*. 2012;9:8-14.
57. Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: Real-world outcomes in patients with type 2 diabetes. *Curr Med Res Opin*. 2012;28(3):439-46.
58. Chung KC, Shauver MJ, Yin H, Kim HM, Baser O, Birkmeyer JD. Variations in the use of internal fixation for distal radius fracture in the United States Medicare population. *J Bone Joint Surg*. 2011;93(23):2154-62.
59. Xie L, Wei W, Pan C, Du J, Baser O. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens. *Adv Ther*. 2011;28(11):1000-11.
60. Baser O, Wei W, Baser E, Xie L. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen vs. exenatide BID. *J Med Econ*. 2011;14(6):673-80.
61. Baser O, Wang L, Supina D, Sengupta N. Anticoagulation prophylaxis practice patterns in patients undergoing total hip or total knee replacement in a U.S. health plan. *Formulary*. 2011;46:486-500.
62. Baser O, Supina D, Sengupta N, Wang L. Anticoagulation bridging therapy patterns in patients undergoing total hip or total knee replacement in a U.S. health plan: Real-world observations and implications. *Am Health Drug Ben*. 2011;4(4):240-8.
63. Wang L, Sengupta N, Baser O. Risk of venous thromboembolism and prophylaxis use in hospitalized medically ill U.S. patients in 180 days post-hospital discharge. *Thrombosis J*. 2011;13(1):15.
64. Baser O, Andrews LM, Wang L, Xie L. Comparison of real-world adherence, health care utilization, and costs for valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium-channel blocker free combination therapy. *J Med Econ*. 2011;14(5):576-83.
65. Baser O, Spalding J, Kothari S, Yuce H, Monsalvo, ML. Cost and clinical consequences of stress/single photon emission computed tomography testing when combined with specific medications. *J Med Econ*. 2011;14(4):433-9.
66. Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid dependence treatments. *Am J Manag Care*. 2011;17:S235-48.
67. Baser O, Chalk M, Rawson R, Gastfriend DR. Alcohol dependence treatments: Comprehensive health care costs, utilization outcomes and pharmacotherapy persistence. *Am J Manag Care*. 2011;17:S222-34.

68. Baser O, Supina D, Wang L, Sengupta N. Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery. *Curr Med Res Opin.* 2011;27(2):423-9.
69. Baser O. Prevalence and economic burden of venous thromboembolism after total hip arthroplasty or total knee arthroplasty. *Am J Manag Care.* 2011;17:S6-8.
70. Birkmeyer JD, Gust C, Baser O, Dimick J, Skinner J, Sutherland JM. Medicare payments for common inpatient procedures, implications for episode-based payment bundling. *Health Serv Res.* 2010;45(6 Pt 1):1783-95.
71. Baser O, Bouchard J, DeLuzio T, Henk H, Aagren M. Assessment of adherence and health care costs of insulin device (Flexpen) versus conventional vial/syringe. *Adv Ther.* 2010;27(2):94-104.
72. Baser O, Supina D, Sengupta N, Wang L, Kwong L. Impact of postoperative venous thromboembolism on Medicare recipients undergoing total hip replacement or total knee replacement surgery. *Am J Health-Syst Pharm.* 2010;67:1438-45.
73. Birkmeyer NJ, Share D, Baser O, *et al.* Preoperative placement of inferior vena cava filters and outcomes after gastric bypass surgery. *Ann Surg.* 2010;252(2):313-8.
74. Baser O, Fan Z, Dimick JB, Staiger D, Birkmeyer JD. Outlier payments for cardiac surgery and hospital quality. *Health Affairs.* 2009;28(4):1154-60.
75. Baser O. Too much ado about instrumental variable approach: Is the cure worse than the disease? *Value Health.* 2009;12(8):1201-9.
76. Sihler KC, Baser O, Birkmeyer NJ, Birkmeyer JD. Statin use reduces the risk of post-operative infections and respiratory complications from non-cardiac general surgery. *J Surg Res.* 2009;151(2):173-5.
77. Dimick JB, Baser O, Staiger DO, Birkmeyer JD. Composite measures for predicting surgical mortality in the hospital. *Health Affairs.* 2009;28(4):1189-98.
78. Englesbe MJ, Dimick JB, Fan Z, Baser O, Birkmeyer JD. Case mix, quality and high-cost kidney transplant patients. *Am J Transplant.* 2009;9(5):1108-14.
79. Englesbe M, Fan Z, Baser O, Birkmeyer J. Mortality in Medicare patients undergoing surgery in July in teaching hospitals. *Ann Surg.* 2009;249:871-6.
80. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's statement on antipsychotic drugs and diabetes. *Diabetes Care.* 2009;32(6):1037-42.
81. Staiger DO, Dimick JB, Baser O, Fan Z, Birkmeyer JD. Empirically derived composite measures of surgical performance. *Med Care.* 2009;47(2):226-33.
82. Sunycz JA, Mucha L, Baser O, Barr CE, Amonkar MM. Impact of compliance and persistence with bisphosphonate therapy on healthcare costs and utilization. *Osteoporosis Int.* 2008;19(10):1421-9.
83. Baser O, Palmer L, Stephen J. The estimation power of alternative comorbidity indices. *Value Health.* 2008;11:946-55.
84. Birkmeyer N, Baser O, Arden M, Gu N, Birkmeyer JD. Socioeconomic status and surgical mortality in the elderly. *Med Care.* 2008;46(9):893-9.

85. Baser O. Modeling transformed health care costs with unknown heteroskedasticity. *Appl Econ Res Bull.* 2007;1:1-6.
86. Baser O. Choosing propensity score matching over regression adjustment for causal inference: When, why and how it makes sense. *J Med Econ.* 2007;10:379-91.
87. Baser O. Propensity score matching with limited overlap. *Econ Bulletin.* 2007;(9)8:1-8.
88. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. The spectrum of healthcare costs associated with herpes zoster: Acute pain vs. postherpetic neuralgia. *J Am Geriatr Soc.* 2007;55(8):1168-75.
89. Foley K, Foster SA, Meadows ES, Baser O, Long SR. Assessment of clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. *Med Care.* 2007;45(9):902-6.
90. Hutchings A, Calloway M, Choy E, Hooper M, Hunter D, Jorday J, Zhang Y, Baser O, Palmer L. The longitudinal examination of arthritis pain (LEAP) study: Relationship between weekly fluctuations in participant-rated joint pain and health outcomes. *J Rheum.* 2007;34(11):2291-300.
91. Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS. Health care costs associated with prostate cancer, androgen deprivation therapy, and bone complications. *J Urol.* 2007;178(4):1423-8.
92. Wong S, Ji H, Hollenbeck B, Morris A, Baser O, Birkmeyer J. Lymph node counts and hospital survival rates after resection from colon cancer. *JAMA.* 2007;298(18):2149-54.
93. Baser O. Using propensity score matching techniques for average treatment effect: Application to Triptan use. Proceedings of International Conference on Health Policy Research, Section on Health Policy Statistics [CD-ROM] Boston, MA: *American Statistical Association.* 2007;4334-9.
94. Ozminowski R, Goetzel R, Shechter D, Stapleton CD, Baser O, Lapin PJ. Predictors of preventive service's use among Medicare beneficiaries. *Health Care Financing Review.* 2006;27(3):5-23.
95. Robinson RL, Long SR, Chang S, Able S, Baser O, *et al.* Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: Analysis of administrative claims. *J Managed Care Pharm.* 2006;12(1):43-54.
96. Baser O. Too much ado about propensity score models? Comparing the methods of propensity score matching. *Value Health.* 2006;9(6):377-85.
97. Gibson TB, Mark TL, Axelsen K, Baser O, *et al.* Impact of statin copayments on adherence and medical care utilization and expenditures. *Am J Managed Care.* 2006;12(12):11-19.
98. Baser O, Gardiner J, Bradley C, Yuce H, Given B. Longitudinal analysis of censored medical cost data. *Health Econ.* 2006;15(5):513-25.
99. Baser O, Crown HW, Pollicino C. Guidelines for selecting among different types of bootstraps. *Curr Med Res Opin.* 2006;22(4):799-808.
100. Finkel S, Kozma C, Long S, Greenspan A, Mahmoud R, Baser O, Engelhart L. Risperidone treatment in elderly dementia patients: Relative risk of cardiovascular adverse events versus other antipsychotics. *Int Psychogeriatr.* 2005;17(4):1-13.

101. Baser O, Gardiner J, Bradley C, Given C. Estimation from censored medical cost data. *Biometrical J.* 2004;46:351-63.
102. Baser O, Pema E. Publications over the academic life-cycle: Evidence for academic economists. *Econ Bulletin.* 2004;1(1):1-8.
103. Crown WH, Berndt ER, Baser O, *et al.* Benefit plan design and prescription drug utilization among asthmatics: Do patient copayments matter? *Front Health Policy Res.* 2004;7:95-127.
104. Baser O, Bradley C, Gardiner J, *et al.* Testing and correcting non-random selection bias due to censoring: application to medical costs. *Health Serv Outcomes Res Methodol.* 2003;4:93-107.
105. Baser O, Pema E. The returns of publications for economics faculty. *Econ Bulletin.* 2003;1(1)1-13.
106. Bradley JC, Given C, Baser O, Gardiner J. Influence of surgical and treatment choices on the cost of breast cancer care. *Eur J Health Econ.* 2003;4:96-101.

KİTAP

1. Baser O. *Modeling Healthcare Costs.* Ann Arbor, MI: 2012:82.

KİTAP BÖLÜMLERİ

1. Crown HC, Berndt ER, Baser O, Finkelstein SN, Witt PW, Maguire J, Haver KE. Benefit plan design and prescription drug utilization among asthmatics: Do patient co-payments matter? *Frontiers in Health Policy Research.* MIT Press; 2004;7:95-127.

SUNUMLAR

1. Baser O. Cost saving initiatives in health care: Reducing variation in quality of care, bundled payment system and comparative effectiveness research, *Boğaziçi Üniversitesi, İstanbul, Türkiye,* Kasım, 1, 2013.
2. Baser O. Estimation of health care costs, *Sosyal Güvenlik Kurumu, Ankara, Türkiye,* Eylül 28, 2013.

DİĞER YAYINLAR

1. Brixner DI, Dhawan R, Miao R, Sung J, Wang L, Baser O, Mehta J. Utilization patterns of abiraterone acetate before and after chemotherapy in patients with metastatic castration-resistant prostate cancer in the Veterans Health Administration System (Abstract). *50th American Society of Clinical Oncology (ASCO) Annual Meeting.* Chicago, IL. 2014;(abstract e16014).
2. Bui CN, Spalding JR, Wang L, Baser O. Treatment timing of life-extending therapies and adherence of corticosteroid among castration-resistant prostate cancer patients with conditions sensitive to corticosteroid use (Abstract). *49th American Society of Clinical Oncology (ASCO) Annual Meeting.* Chicago, IL. *J Clin Oncol.* Yayın Tarihi: Mayıs 2013.
3. Wang L, Fritschel E, Li L, Zhang J, Baser O. An overview of clinical and economic outcomes of U.S. veteran colorectal cancer patients (Abstract). *49th American Society of Clinical Oncology (ASCO) Annual Meeting.* Chicago, IL. *J Clin Oncol.* 2013(suppl; abstr e14689).

4. Wang L, Fritschel E, Li L, Zhang J, Baser O. An assessment of clinical and economic outcomes of U.S. veteran lung cancer patients (Abstract). *49th American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. *J Clin Oncol*. 2013(suppl; abstr e19122).
5. Wang L, Fritschel E, Li L, Huang A, Baser O. An examination of medical and economic outcomes of U.S. veteran breast cancer patients (Abstract). *49th American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. *J Clin Oncol*. 2013(suppl; abstr e12010).
6. Baser O, Fritschel E, Wang L. Geographic trends in critical limb ischemia prevalence in the United States. *ISPOR Connections*. 2012;18(3):15-16.
7. Baser O, Wei W, Henk H, Xie L. Survival, health care utilization, and cost of metastatic triple-negative breast cancer in a US managed care setting (Abstract). *47th American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. *J Clin Oncol*. 29:2011(suppl; abstr e11576).
8. Xie L, Wei W, Henk H, Baser O. Risk of recurrence and economic burden of early-stage triple-negative breast cancer in a US managed care setting (Abstract). *47th American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL. *J Clin Oncol*. 29:2011(suppl; abstr e11563).
9. Baser O. Propensity score matching with multi-level categories. *ISPOR Connections*. 2008;14(2):4-8.
10. Başer O. Değere Bağlı Sağlık Sistemi. *Sağlık Ekonomisi*. 2009:1-10. (Türkçe)

KONFERANS SUNUMLARI

1. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding and associated costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban or warfarin. *European Society of Cardiology (ESC) Congress 2016*. Rome, Italy: 27-31 August 2016.
2. Black CM, Hu X, Khandker RK, Ambegaonkar BM, Kariburyo MF, Xie L, Baser O, Yuce H. Comparison of all-cause mortality rate and economic burden between newly diagnosed Alzheimer's disease patients who received anti-dementia treatment versus not: A longitudinal retrospective study. *Alzheimer's Association International Conference (AAIC) Annual Conference*. Toronto, Canada: July 24-28, 2016.
3. Cai J, Wang Y, Baser O, Xie L, Diels J, Neslusan C, Chow W. Comparative persistence with antihyperglycemic agents (AHA) used to treat type 2 diabetes mellitus (T2DM) in the real world. *American Diabetes Association (ADA) 76th Scientific Sessions*. New Orleans, LA: June 10-14, 2016.
4. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Comparing health care resource utilization and costs among obese patients in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
5. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Assessing the economic burden and health care utilization of attention deficit/hyperactivity disorder among US Medicaid patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
6. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Evaluating asthma-related expenses and health care resource utilization among children in the US Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.

7. Ogbomo A, Tan H, Kariburyo F, Xie L, Baser O. Assessing the economic burden and health care resource utilization of US veterans with chronic obstructive pulmonary disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
8. Ogbomo A, Zhao Y, Kariburyo MF, Xie L, Yuce H, Baser O. Retrospective analysis of the economic burden of patients diagnosed with congestive heart failure in the California Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
9. Ogbomo A, Tan H, Kariburyo F, Xie L, Baser O. Assessing health care resource utilization and costs among US veterans diagnosed with asthma. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
10. Keshishian A, Tan H, Xie L, Baser O. Examination of the economic burden of dyslipidemia in the veterans health administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
11. Kariburyo F, Du J, Xie L, Baser O. Examining the health care resource utilization and economic burden among rheumatoid arthritis patients with different routine assessment of patient index data 3 scores: A probabilistic matching study. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
12. Kariburyo F, Du J, Xie L, Baser O. Assessing the economic burden of rheumatoid arthritis patients with different clinical disease activity index scores: a probabilistic matching study. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
13. Tan H, Xie L, Wang Y, Yuce H, Baser O. Examine the burden of illness of US Medicare patients diagnosed with cataract. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
14. Tan H, Xie L, Baser O, Yuce H, Wang Y. Evaluating the economic burden and health care utilization of anemia in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
15. Zhang Q, Zhao Y, Keshishian A, Xie L, Yuce H, Baser O. Evaluating the economic burden and health care utilization of coronary artery disease in the US Medi-Cal population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
16. Keshishian A, Du J, Xie L, Yuce H, Baser O. Demographic and socioeconomic characteristics that impact selection of oral anticoagulants among non-valvular atrial fibrillation patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
17. Sanon M, Xie L, Bent-Ennakhil N, Coste F, Wang Y, Kariburyo MF, Neumann P, Fillit H. Health care utilization and costs in treated and non-treated US patients newly diagnosed with Alzheimer's disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.

18. Cheng E, Wang L, Morgenstern D, Asner I, Ta J, Jan A, Xie L, Kariburyo F, Wang Y, Meadows E. Healthcare costs among men with clinically localized prostate cancer managed with observation strategies versus immediate treatment in an integrated health care system. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
19. Pandya S, Du H, Wang L, Yuce H, Baser O. Mortality and rehospitalization rates among patients with chronic obstructive pulmonary disease in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
20. Bashyal R, Du H, Wang L, Yuce H, Baser O. Mortality and prevalence of major depressive disorder in the US Medicare population from 2008-2013. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
21. Pandya S, Du H, Wang L, Yuce H, Baser O. Mortality and rehospitalization rates among hospitalized congestive heart failure patients in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
22. Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of alcohol dependence among US veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
23. Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with depressive disorder in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
24. Bashyal R, Du H, Wang L, Baser O. Examining the incidence and prevalence of bipolar disorder among U.S. veteran patients from 2011 to 2015. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
25. Pandya S, Du H, Wang L, Baser O. Examining the prevalence and incidence rates among patients with drug dependence in the US veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
26. Bashyal R, Du H, Wang L, Yuce H, Baser O. Examining the mortality and readmission rates of patients diagnosed with stroke in the US Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
27. Pesa JA, Wang L, Yuce H, Baser O. Proton pump inhibitor utilization among patients with hepatitis C virus (HCV). *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting*. Washington DC: May 21-25, 2016.
28. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Mardekian J, Mendoza M, Singhal S, Patel C, Odell K, Trocio J. Real-world comparison of major bleeding risk among untreated non-valvular atrial fibrillation patients and those initiating apixaban, dabigatran, rivaroxaban, or warfarin. *American College of Cardiology (ACC) 65th Annual Scientific Session & Expo*. San Diego, CA: April 2-4, 2016.
29. Alpesh AN, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. Early comparison of major bleeding, stroke and associated medical costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban or warfarin. *American Society of Hematology (ASH) Annual Meeting and Exposition*. Orlando, FL: December 5-8, 2015. [oral presentation]

30. Xie L, Wang Y, Tan H, Ogbomo A, Baser O, Yuce H. Trends in prevalence and incidence rates of type 2 diabetes mellitus in the Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
31. Keshishian A, Wang Y, Xie L, Baser O, Yuce H. Examining the economic burden and health care utilization of menopausal women in the U.S. Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
32. Baser O, Ogbomo A, Tan H, Du J, Xie L. Evaluation of the burden of opioid abuse among US veteran patients. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
33. Xie L, Tan H, Ogbomo A, Wang Y, Baser O, Yuce H. Evaluation of the burden of Parkinson's disease in Medicare and linked long term care populations. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
34. Fox KM, Wang L, Quek RGW, Gandra SR, Li L, Baser O. Long-term increased inpatient and outpatient visits associated with cardiovascular events: A large United States real world study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress*. Milan, Italy: 7-11 November 2015.
35. Amin A, Keshishian A, Xie L, Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singhal S, Patel C, Odell K, Trocio J. Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin. *American Heart Association (AHA) Scientific Sessions 2015*. Orlando, FL: November 7-11, 2015.
36. Masseria C, Kariburyo MF, Mardekian J, Lee TC, Ravee Y, Phatak H, Baser O, Hamilton M, Xie L. Venous thromboembolism recurrence and bleeding risk among cancer patients using a large commercial database. *American Heart Association (AHA) Scientific Sessions 2015*. Orlando, FL: November 7-11, 2015.
37. Keshishian A, Xie L Baser O, Price K, Vo L, Singh P, Bruno A, Mardekian J, Tan W, Singha S, Patel C, Odell K, Trocio J. Comparison of short term bleeding-related health care utilization and costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivoxaban or warfarin. *American College of Chest Physicians CHEST Annual Meeting 2015*. Montreal, QC, Canada: 24-28 October 2015.
38. Pesa J, Wang L, Yuce H, Baser O. Comparing costs and resource utilization between patients with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in California Medicaid (Medi-Cal). *U.S Psychiatric & Mental Health Congress*. San Diego, CA: September 10-13, 2015.
39. Baser O, Lewis-Beck C, Fritschel E, Baser E, Wang L. Applied comparison of meta-analysis techniques. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 5th Latin America Conference*. Santiago, Chile: 6-8 September 2015.
40. Nguyen C, Xie L, Alley S, Baser O, Wang Z. Epidemiology and economic burden of serotonin syndrome with concomitant use of serotonergic agents in the U.S. clinical practice. *American Society of Clinical Psychopharmacology (ASCP) 2015 Annual Meeting*. Miami, FL: June 22-25, 2015.
41. Alley S, Nguyen C, Xie L, Baser O, Wang Z. Epidemiology and economic burden of serotonin syndrome with concomitant use of serotonergic agents in the US clinical practice. *American Association of Nurse Practitioners (AANP) 2015 National Conference*. New Orleans, LA: June 9-14, 2015.

42. Xie L, Keshishian A, Du J, Baser O. Assessing the economic burden and health care resource utilizations of U.S. Medicare patients with myeloproliferative neoplasms. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
43. Xie L, Keshishian A, Du J, Baser O. Assessing the economic burden of U.S. Medicare patients diagnosed with Non-Hodgkin's lymphoma. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
44. Xie L, Kariburyo MF, Wang D, Baser O. A descriptive analysis of patient characteristics and health care burden associated with chronic obstructive pulmonary disease in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
45. Baser O, Kariburyo MF, Du J, Xie L. Comparing healthcare resource utilization and costs among schizophrenic patients who initiated typical vs. atypical long-acting injectables in the U.S. veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
46. Xie L, Keshishian A, Du J, Baser O. Examining the fracture-related cost burden and healthcare resource utilization post-menopause in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
47. Xie L, Wang Y, Keshishian A, Baser O. Comparing the healthcare utilization and costs of early- and late-stage Alzheimer's disease patients residing in long-term care facilities. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
48. Xie L, Keshishian A, Wang Y, Baser O. Evaluating fracture-related expenses and health care resource utilization among post-menopausal women in the U.S. Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
49. Mao X, Shrestha S, Baser O, Wang L. Assessing the health care resource utilization and economic burden among U.S. cardiovascular disease patients in the Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
50. Li L, Shrestha S, Baser O, Yuce H, Wang L. Mortality and rehospitalization rates among hospitalized pneumonia patients in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
51. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Demographic distribution and economic burden of patients diagnosed with rheumatoid arthritis in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
52. Li L, Shrestha S, Baser O, Yuce H, Wang L. Examining prevalence, incidence and mortality rates among opioid-dependent patients in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.

53. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Health care cost burden and demographic distribution of patients diagnosed with psoriatic arthritis in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
54. Huang A, Shrestha S, Baser O, Yuce H, Wang L. Health care resource utilization and costs among diabetes patients residing in long-term care facilities. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
55. Huang A, Shrestha S, Baser O, Yuce H, Wang L. Health care resource utilizations and costs among migraine patients in the U.S. Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
56. Huang A, Shrestha S, Baser O, Yuce H, Wang L. A retrospective analysis of health care resource utilization and the economic burden among U.S. long-term care facility patients diagnosed with stroke. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
57. Li L, Mao X, Shrestha S, Baser O, Yuce H, Wang L. Demographic distribution and health care burden of patients diagnosed with ankylosing spondylitis in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
58. Li L, Shrestha S, Baser O, Yuce H, Wang L. Prevalence and incidence rates among alcohol-dependent patients in the U.S. Medicare population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
59. Mao X, Shrestha S, Baser O, Wang L. A retrospective analysis of the economic burden among patients diagnosed with chronic migraine using the Veterans Health Administration medical dataset. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
60. Li L, Shrestha S, Baser O, Wang L. Evaluating trends in chronic pain prevalence in the United States Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
61. Xie L, Du J, Kariburyo MF, Baser O. A descriptive analysis of patient characteristics, bleeding and recurrence risk among U.S. veteran patients diagnosed with venous thromboembolism. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
62. Fox KM, Wang L, Gandra SR, Quek RGW, Li L, Baser O. Long-term economic burden associated with cardiovascular events among high-risk patients with hyperlipidemia. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
63. Xie L, Wang Z, Alley S, Baser O, Nguyen C. Healthcare utilization and costs of serotonin syndrome with concomitant use of serotonergic agents. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.

64. Masseria C, Kariburyo MF, Mardekian J, Lee T, Phatak H, Baser O, Xie L. Clinical outcomes and treatment patterns of venous thromboembolism among cancer patients in a large commercial database. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
65. Velez FF, Baser O, Xie L. Adherence and persistence to anti-epileptic drugs among U.S. veterans diagnosed with epilepsy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual International Meeting*. Philadelphia PA: May 16-20, 2015.
66. Nguyen C, Xie L, Alley S, Baser O, Wang Z. Incidence of serotonin syndrome with concomitant use of serotonergic agents in the U.S. veteran population. *American Psychiatric Association (APA) 168th Annual Meeting*. Toronto, Ontario, Canada: May 16-20, 2015.
67. Quek RGW, Fox KM, Wang L, Li L, Gandra SR, Wong N. Lipid lowering treatment trends among diabetes patients with very high cardiovascular disease risk: A real-world study. *American Association of Clinical Endocrinologists (AAACE) 24th Annual Scientific & Clinical Congress*. Nashville, TN: May 13-17, 2015.
68. Xie L, Vo L, Keshishian A, Price K, Singh P, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and costs between non-valvular atrial fibrillation patients treated with either apixaban or warfarin. *American Heart Association (AHA) Quality of Care and Outcomes Research Scientific Sessions 2015*. Baltimore, MD: April 29 - May 1, 2015.
69. Wang Z, Xie L, Alley S, Baser O, Nguyen C. Incidence of serotonin syndrome with concomitant use of serotonergic agents in the U.S. clinical practice. *Society of General Internal Medicine (SGIM) 38th Annual Meeting*. Toronto, Ontario, Canada: April 22-25, 2015.
70. Baser O, Griffith J, Roy S, Xie L, Ganguli A. Impact of switching among tumor necrosis factor inhibitors (TNF) on health care resource utilization and costs in patients with rheumatoid arthritis. *Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting & Expo*. San Diego, CA: April 7-10, 2015.
71. Velez F, Baser O, Xie L. Cost analyses among U.S. veterans diagnosed with epilepsy and treated with anti-epileptic drug monotherapy or adjunctive therapy. *Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting & Expo*. San Diego, CA: April 7-10, 2015.
72. Xie L, Vo L, Keshishian A, Price K, Mardekian J, Bruno A, Baser O, Kim J, Tan W, Trocio J. Comparison of hospital length of stay and costs between non-valvular atrial fibrillation patients treated with either apixaban or warfarin. *Academy of Managed Care Pharmacy (AMCP) 27th Annual Meeting & Expo*. San Diego, CA: April 7-10, 2015.
73. Wang L, Baser O, Barron R. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. *American Society of Hematology (ASH) Annual Meeting and Exposition*. San Francisco, CA: December 6-9, 2014.
74. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Association of out-of-range international normalized ratio (INR) values and adverse clinical outcomes among newly initiated warfarin patients with non-valvular atrial fibrillation and comorbid diabetes. *American Heart Association (AHA) Scientific Sessions 2014*. Chicago, IL: November 15-19, 2014.
75. Li L, Shrestha S, Baser O, Wang L. Healthcare utilization and costs of breast cancer in the Medicaid program. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.

76. Li L, Shrestha S, Baser O, Wang L. Healthcare utilization and costs of Medicaid program services for patients diagnosed with multiple sclerosis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
77. Li L, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden among Cushing's disease patients in the U.S. Medicaid program. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
78. Li L, Shrestha S, Baser O, Wang L. Evaluation of the economic burden of menopausal women in the U.S. Medicaid program. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
79. Huang A, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden of U.S. long-term care facility residents diagnosed with Parkinson's disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
80. Huang A, Shrestha S, Baser O, Wang L. Retrospective analysis of the economic burden of long-term care facility residents diagnosed with Alzheimer's disease in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
81. Xie L, Kariburyo MF, Du J, Baser O. Examination of the burden of illness of U.S. Medicare patients diagnosed with chronic obstructive pulmonary disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
82. Xie L, Kariburyo MF, Du J, Baser O. Assessing the economic burden and health care utilization of U.S. Medicare patients diagnosed with melanoma. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014. [FINALIST RESEARCH AWARD]
83. Xie L, Dysinger AH, Kariburyo MF, Du J, Baser O. Evaluation of the burden of illness of U.S. Medicare patients diagnosed with hyperpotassemia. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
84. Xie L, Kariburyo MF, Wang Y, Baser O. Evaluating the economic burden and health care utilizations of U.S. veteran patients diagnosed with chronic hepatitis C. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014. [FINALIST RESEARCH AWARD]
85. Xie L, Kariburyo MF, Wang Y, Baser O. Health care costs and utilization of U.S. veteran patients diagnosed with pancreatic cancer. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
86. Xie L, Kariburyo MF, Wang Y, Baser O. Comparison of the economic burden and health care utilizations of U.S. veteran patients diagnosed with type 2 diabetes mellitus. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
87. Xie L, Dysinger AH, Wang Y, Kariburyo MF, Baser O. Prevalence of cystic fibrosis among the U.S. national Medicaid population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.

88. Baser O, Kariburyo MF, Altinbas A, Baser E. Economic burden and complications of hepatitis C virus patients with and without peginterferon and ribavirin treatment in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
89. Baser O, Kariburyo MF, Baser E, Altinbas A. Cost of cirrhosis among patients diagnosed with hepatitis C virus in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
90. Baser E, Baser O, Altinbas A, Kariburyo MF. Pharmacy cost calculator for hepatitis C virus patients in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual European Congress*. Amsterdam, The Netherlands: 8-12 November 2014.
91. Levin PA, Wei W, Gill J, Buysman E, Grabner M, Xie L, Baser O, Chu JW. Treatment patterns and outcomes in managed care patients with type 2 diabetes initiating injectable therapies: A pooled analysis from the INITIATOR Study. *Academy of Managed Care Pharmacy (AMCP) 2014 Nexus Meeting*. Boston, MA: October 7-10, 2014.
92. Wei W, Brekke LN, Buysman E, Grabner M, Ke X, Xie L, Baser O. A personalized-medicine approach to evaluate real-world treatment benefits of patients with type 2 diabetes mellitus initiating different injectable therapies. *Academy of Managed Care Pharmacy (AMCP) 2014 Nexus Meeting*. Boston, MA: October 7-10, 2014.
93. Miao R, Wei W, Xie L, Baser O. Impact of switching basal insulin analogs on clinical and economic outcomes in patients with type 2 diabetes in a national managed care plan setting. *Academy of Managed Care Pharmacy (AMCP) 2014 Nexus Meeting*. Boston, MA: October 7-10, 2014.
94. Yu H, Strutton D, Roberts C, Baser O, Wang L. *Clostridium difficile* associated disease in the US elderly population. *54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2014* Washington DC, USA: September 5-9, 2014. [oral presentation]
95. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Warfarin discontinuation in patients with unprovoked venous thromboembolism: A large US insurance database analysis. *European Society of Cardiology (ESC) Congress 2014*. Barcelona, Spain: August 30-September 3, 2014.
96. Levin P, Wei W, Miao R, Ye F, Xie L, Baser O, Gill J. Therapeutically exchangeable? A real-world outcome study of switching between basal insulin analogs among T2DM patients. *American Diabetes Association (ADA) 74th Annual Scientific Sessions*. San Francisco, CA: June 13-17, 2014.
97. Zedler B, Xie L, Wang L, Joyce A, Vick C, Brigham J, Kariburyo MF, Edwards E, Baser O, Murrelle L. Development of a predictive questionnaire for prescription opioid-related overdose or respiratory/CNS depression. *International Conference on Opioids (ICOO)*. Boston, MA: June 8-10, 2014.
98. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Baser O. Variation trends in asthma prevalence in the U.S. Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014. [FINALIST RESEARCH AWARD]
99. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Baser O. Examining diabetes prevalence in the United States using a 2008-2009 Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.

100. Wang L, Xie L, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Prevalence of hepatitis B virus infection in the U.S. Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
101. Xie L, Wang L, Zhang J, Shrestha S, Wang Y, Baser O. Examining hepatitis C virus prevalence in the U.S. Medicaid population from 2008 to 2009 *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
102. Baser O, Wang L, Huang A, Wang Y, Kariburyo MF, Xie L. Examining the burden of illness of U.S. veteran patients diagnosed with bipolar disorder. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
103. Baser O, Xie L, Huang A, Du J, Wang Y, Wang L. Evaluation of the burden of depression among U.S. veteran patients. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
104. Wang L, Xie L, Li L, Wang Y, Du J, Baser O. Assessing the health care burden of asthma patients in the U.S. Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
105. Wang L, Xie L, Li L, Kariburyo MF, Wang Y, Baser O. Evaluation of economic burden and health care utilizations for U.S. Medicare patients with rheumatoid arthritis. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
106. Xie L, Wang L, Li L, Wang Y, Baser O. The burden of illness of osteoporosis patients in the U.S. Medicare population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
107. Wang L, Xie L, Li L, Wang Y, Kariburyo MF, Baser O. Economic burden and health care utilizations of U.S. Medicare patients diagnosed with prostate cancer. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
108. Xie L, Wang L, Li L, Wang Y, Du J, Baser O. Evaluation of the burden of general cardiovascular disease among U.S. Medicare patients. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
109. Seal BS, Xie L, Rietschel P, Baser O. Compare demographic and clinical characteristics among colorectal cancer patients with a different number of treatment lines in the U.S. veterans health administration *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
110. Seal BS, Xie L, Rietschel P, Baser O. Descriptive analysis of treatment patterns and mortality of U.S. veteran patients with colorectal cancer. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014. [Podium presentation]
111. Xie L, Dysinger AH, Wang L, Zhang J, Shrestha S, Wang Y, Baser O. Autism prevalence in children among the U.S. Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014. [FINALIST RESEARCH AWARD]

112. Wang L, Xie L, Dysinger AH, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Assessing Lyme disease prevalence in the U.S. Medicaid population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
113. Xie L, Dysinger AH, Wang L, Zhang J, Shrestha S, Wang Y, Kariburyo MF, Baser O. Prevalence and trends in cystic fibrosis among the U.S. Medicaid population in 2008 and 2009. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
114. Wang L, Dysinger AH, Xie L, Huang A, Wang Y, Baser O. Assessing the economic burden and health care utilizations of U.S. veteran patients with post-traumatic stress disorder after unstable angina. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
115. Claflin AB, Xie L, Liu X, Mardekian J, Phatak H, Tan W, Baser O. Anticoagulant use and bleeding risk in patients with venous thromboembolism: A nested case-control study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting*. Montreal, QC, Canada: May 31-June 4, 2014.
116. Xie L, Frech-Tamas F, Baser O. Impact of antihypertensive pill burden on patient adherence. *American Society of Hypertension (ASH) 2014 Annual Scientific Meeting and Exposition*, New York, NY: May 16-20, 2014.
117. Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, Simpson KN. Human immunodeficiency virus burden of illness and treatment patterns among U.S. veteran patients. *Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo*. Tampa, FL, USA: April 1-4, 2014.
118. Olufade T, Wang L, Devine S, Baser O, Lo Re V, III. Hepatic decompensation in HIV/HBV/HCV patients and the impact of HBV therapy. *Conference on Retroviruses and Opportunistic Infections (CROI) 2014*. Boston, MA: March 3-6, 2014.
119. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Ramacciotti E. Bleeding incidence among patients with venous thromboembolism: A large US insurance database analysis. *55th American Society of Hematology (ASH) Annual Meeting and Exposition*. New Orleans, LA, USA: December 7-10, 2013.
120. Bui CN, Spalding JR, Wang L, Baser O. Treatment timing of life-extending therapies and adherence to corticosteroids among metastatic castration-resistant prostate cancer patients with conditions sensitive to corticosteroid use. *5th European Multidisciplinary Meeting on Urological Cancers (EMUC)*. Marseille, France: November 15-17, 2013.
121. Wang L, Xie L, Du J, Li L, Baser O. Examining the burden of illness of U.S. veteran patients diagnosed with Alzheimer's disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
122. Wang L, Xie L, Li L, Kariburyo MF, Baser O. Assessing the economic burden and healthcare utilizations of U.S. veteran patients diagnosed with the hepatitis C virus. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.

123. Xie L, Wang L, Kariburyo MF, Li L, Wang Y, Baser O. Comparison of the health care costs and utilizations between patients diagnosed with the hepatitis B virus versus those without. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
124. Wang L, Xie L, Du J, Li L, Baser O. Examining the burden of illness of U.S. veteran patients diagnosed with obesity. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
125. Wang L, Dysinger AH, Xie L, Du J, Huang A, Baser O. Evaluation of the burden of illness of skin cancer among U.S. veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
126. Wang L, Xie L, Li L, Wang Y, Kariburyo MF, Baser O. Evaluation of the burden of illness of colorectal cancer among U.S. veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
127. Wang L, Xie L, Kariburyo MF, Li L, Wang Y, Baser O. Examining the burden of illness of U.S. veteran patients with prostate cancer. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
128. Xie L, Wang L, Kariburyo MF, Huang A, Baser O. A comparison of the economic burden and health care utilizations of U.S. veteran patients diagnosed with diabetes. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
129. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Effects of excess use of coronary angiography and its association with mortality rates, health care costs and hospital quality in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
130. Liu X, Xie L, Phatak H, Mardekian J, Tan W, Baser O, Schneider RF, Ramacciotti E. Anticoagulant use in the U.S. hospitalized patients with acute venous thromboembolism. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
131. Wang L, Xie L, Du J, Li L, Baser O. A comparison of the economic burden and health care utilizations of U.S. veteran patients diagnosed with hypertension. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013. [FINALIST RESEARCH AWARD]
132. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Impact of comorbidity burden on real-world healthcare costs of rheumatoid arthritis patients in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
133. Baser O, Baser E, Altinbas A, Burkan A. Effects of claims-based rheumatoid arthritis severity on biologic therapy use and health care costs in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
134. Baser O, Wang L, Li L, Huang A, Xie L. Application of a data visualization tool: Treatment patterns of veteran patients with ankylosing spondylitis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.

135. Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Durguner B, Baser O, Akkoc N. Medical costs of patients with rheumatoid arthritis and association with global disease activity in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
136. Xie L, Dysinger AH, Wang L, Xie L, Du J, Huang A, Baser O. Assessing the economic burden and health care utilizations of U.S. veteran patients diagnosed with post-traumatic stress disorder. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
137. Xie L, Wang L, Du J, Li L, Baser O. Comparing the healthcare costs and utilizations between patients with anxiety versus those without. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
138. Wang L, Xie L, Li L, Kariburyo MF, Baser O. Assessing the economic burden and health care utilizations of US veteran patients diagnosed with schizophrenia. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
139. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Using an Excel calculator to estimate ankylosing spondylitis costs in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
140. Baser O, Baser E, Altinbas A, Burkan A. Derivation of severity index for rheumatoid arthritis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
141. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. An Excel calculator to estimate rheumatoid arthritis costs in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
142. Wang L, Xie L, Du J, Huang A, Baser O. Assessing the economic burden and healthcare utilizations of US veteran patients diagnosed with chronic kidney disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress*. Dublin, Ireland: November 2-6, 2013.
143. Ray S, Wang L, Martel MJ, Baser O. Variation in patterns of healthcare and survival among patients with brain metastases in the VHA health system. *American Society of Clinical Oncology (ASCO) Quality Care Symposium*. San Diego, CA, USA: November 1-2, 2013.
144. Alemao E, Xie L, Wong R, Litalien G, Baser O. Analysis of non-steroidal anti-inflammatory drug burden among rheumatoid arthritis patients using the Dougados algorithm. *American College of Rheumatology (ACR) Annual Scientific Meeting*. San Diego, CA: October 25-30, 2013.
145. Rosenblatt L, Lobo F, Cockrum P, Wang L, Alemao E, Baser O, Yuce H. Biologic switching rates among patients with rheumatoid arthritis. *American College of Rheumatology (ACR) Annual Scientific Meeting*. San Diego, CA: October 25-30, 2013.
146. Wei W, Zhou S, Miao R, Pan C, Xie L, Baser O, Gill J. Much ado about nothing? A longitudinal retrospective study of patients with type-2 diabetes treated with insulin glargine and switched to insulin detemir. *Society for Medical Decision Making (SMDM) 35th Annual Meeting*. Baltimore, MD: October 20-23, 2013.

147. Wang L, Haider S, Nedrow K, Chambers R, Tawadrous M, Baser O, Simpson K. Burden of illness among United States veteran treatment naïve human immunodeficiency virus infected patients. *2013 American College of Clinical Pharmacy (ACCP) Annual Meeting*. Albuquerque, NM: October 13-16, 2013.
148. Xie L, Pesa J, Durkin M, Clancy Z, Baser O. Healthcare use and cost of patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in a VA population. *65th Institute on Psychiatric Services (IPS) Conference*. Philadelphia, PA: October 10-13, 2013.
149. Xie L, Pesa J, Durkin M, Clancy Z, Baser O. A comparison of healthcare utilization and costs of schizophrenia patients treated with paliperidone palmitate long-acting injection or atypical oral antipsychotics within the Veterans Health Administration. *U.S. Psychiatric and Mental Health Congress*. Las Vegas, NV: September 30-October 3, 2013.
150. Dalal M, Xie L, Baser O, DiGenio A. Adding rapid-acting insulin or GLP-1 receptor agonist to basal insulin in patients with type 2 diabetes: Real world health care costs from a US managed care setting. *European Association for the Study of Diabetes (EASD) Annual Meeting*. Barcelona, Spain: September 23-27, 2013.
151. Wang L, Lewis-Beck C, Baser E, Fritschel E, Baser O. Applied comparison of meta-analysis techniques. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 4th Latin America Conference*. Buenos Aires, Argentina: September 12-14, 2013.
152. Xie L, Du J, Kariburyo MF, Dysinger AH, Wang L, Baser O. Mental disorder treatment, healthcare costs and utilizations for US veterans. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, Quebec, Canada: August 25-28, 2013. [Oral presentation]
153. Baser O, Wang L, Li L, Xie L. Characteristics associated with initiation of intravenous versus subcutaneous injection tumor necrosis factor inhibitors for rheumatoid arthritis patients. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, Quebec, Canada: August 25-28, 2013.
154. Baser O, Du J, Xie L, Dysinger AH, Wang L. Severity Index for Rheumatoid Arthritis: Impact on healthcare costs and utilization. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, Quebec, Canada: August 25-28, 2013.
155. Wang L, Huang A, Fritschel E, Baser O. Tumor necrosis factor treatment patterns in Medicare patients with inflammatory conditions. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, Quebec, Canada: August 25-28, 2013.
156. Wang L, Li L, Fritschel E, Baser O. Overview of the clinical and economic burden of prostate cancer in the U.S. veteran population. *29th International Conference on Pharmacoepidemiology (ICPE) and Therapeutic Risk Management*. Montreal, Quebec, Canada: August 25-28, 2013.
157. Wang L, Wei W, Dalal M, Baser O. Treatment intensification after early failure of metformin or sulfonylurea among VA patients with type 2 diabetes. *American Diabetes Association (ADA) 73rd Scientific Sessions*. Chicago, IL: June 21-25, 2013.
158. Xie L, Wei W, Thayer S, Brekke L, Buysman E, Crown W, Grabner M, Raparla S, Quimbo R, Cziraky M, Baser O, Hu W, Cuddihy R. Insulin or GLP-1? A real-world comparative effectiveness analysis of initiating injectable treatment among patients with type 2 diabetes mellitus failing oral anti-diabetes drugs: pilot data from the INITIATOR Study. *ENDO 2013: Endocrine Society 96th Annual Meeting & Expo*; San Francisco, CA: June 15-18, 2013.

159. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Analysis of health care costs associated with ankylosing spondylitis in Turkey. *European League Against Rheumatism (EULAR) 2013 Annual European Congress of Rheumatology*. Madrid, Spain: June 12-15, 2013.
160. Rosenblatt L, Lobo F, Cockrum P, Wang L, Alemao E, Baser O, Yuce H. Biologic switching rates among patients with rheumatoid arthritis. *European League Against Rheumatism (EULAR) 2013 Annual European Congress of Rheumatology*. Madrid, Spain: June 12-15, 2013.
161. Hamuryudan V, Direskeneli H, Ertenli I, Inanc M, Karaaslan Y, Oksel F, Ozbek S, Pay S, Terzioglu E, Durguner B, Baser O, Akkoc N. Medical costs of patients with rheumatoid arthritis and association with global disease activity in Turkey. *European League Against Rheumatism (EULAR) 2013 Annual European Congress of Rheumatology*. Madrid, Spain: June 12-15, 2013.
162. Barron R, Wang L, Baser O, Langeberg W, Dale DC. Chemotherapy-induced febrile neutropenia (FN) and FN prevention strategies in cancer care in the US Veterans Health Administration. *49th American Society of Clinical Oncology (ASCO) Annual Meeting*: Chicago, IL: May 31-June 4, 2013.
163. Xie L, Du J, Wang L, Yuce H, Baser O. Examination of treatment patterns of ankylosing spondylitis patients in the Veterans Affairs and Medicare databases using a visualization tool. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
164. Xie L, Baser O. Clinical and economic burden of U.S. veteran schizophrenia patients: A real-world evaluation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
165. Wang L, Zhang J, Baser O. Evaluation of the clinical and economic burden of the human immunodeficiency virus in U.S. veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
166. Wang L, Zhang J, Baser O. Evaluation of clinical, treatment characteristics and the economic burden of anxiety in U.S. veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
167. Wang L, Zhang J, Li L, Baser O. Clinical and economic burden of U.S. veteran Alzheimer's disease patients: a real-world evaluation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
168. Wang L, Zhang J, Baser O. Assessing the economic burden and treatment patterns of U.S. veteran chronic kidney disease patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
169. Wang L, Li L, Zhang J, Baser O. Comorbidities and economic burden of multiple sclerosis patients in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
170. Wang L, Li L, Zhang J, Baser O. Assessing the clinical and economic burden of U.S. veteran lung cancer patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.

171. Wang L, Li L, Zhang J, Baser O. Assessing the clinical and economic burden of prostate cancer in the U.S. veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
172. Wang L, Zhang J, Li L, Baser O. Clinical characteristics and treatment patterns of colorectal cancer in United States veterans. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
173. Wang L, Huang A, Baser O. Assessing the clinical and economic burden of U.S. veteran diabetes patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
174. Wang L, Huang A, Baser O. Clinical and economic burden of U.S. veteran chronic obstructive pulmonary disease patients: A real-world evaluation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
175. Wang L, Huang A, Li L, Baser O. Evaluation of the clinical characteristics and economic burden of U.S. veteran patients diagnosed with the hepatitis C virus. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
176. Wang L, Huang A, Baser O. Atrial fibrillation prevalence associated with geographic variation and age in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
177. Wang L, Huang A, Baser O. Geographic variation trends in Crohn's disease prevalence and demographic characteristics in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
178. Wang L, Huang A, Baser O. Assessing the geographic and demographic variation associated with psoriatic arthritis prevalence in the U.S. veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
179. Wang L, Huang A, Baser O. Geographic variation trends in systemic lupus erythematosus prevalence in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
180. Akkoç N, Direskeneli H, Erdem H, Gül A, Kabasakal Y, Kiraz S, Durguner B, Baser O, Hamuryudan V. Ankylosing spondylitis health care costs and associated disease activity scores in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
181. Hamuryudan V, Direskeneli H, Ertenli İ, İnanç M, Karaaslan Y, Oksel F, Özbek S, Pay S, Terzioğlu E, Durguner B, Baser O, Akkoç N. Medical costs of patients with rheumatoid arthritis and its association with global disease activity in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.

182. Xie L, Liu X, Phatak H, Mardekian J, Tan W, Baser O, Schneider RF, Ramacciotti E. Recurrence and risk factors in hospitalized patients with acute venous thromboembolism: A claims database analysis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
183. Xie L, Khandelwal N, Kariburyo F, Baser O. Comparing healthcare costs and utilizations of patients with overactive bladder who were adherent and non-adherent to their medication. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013. [FINALIST RESEARCH AWARD]
184. Xie L, Du J, Kariburyo F, Baser O. Treatment, health care costs and utilizations of U.S. veterans with mental disorders. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
185. Baser O, Du J, Dysinger AH, Wang L, Xie L. A real-world evaluation of the clinical and economic burden of U.S. veteran patients with post-traumatic stress disorder. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
186. Xie L, Du J, Baser O. Comorbidities, medications, health care costs and utilizations of U.S. veteran patients with gastroesophageal reflux disease. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
187. Baser O, Du J, Kariburyo F, Xie L. A solution for under-diagnosed post-menopause: Probabilistic linkage of claims and registry data. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
188. Baser O, Huang A, Li L, Wang L. Obese patients in the U.S. veteran population: A health care cost and utilization analysis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting*. New Orleans, LA: May 18-22, 2013.
189. Baser O, Chan W, Wang L, Waltman-Johnson K, Xie L. Comparison of real-world cardiovascular-related healthcare costs of newly initiated valsartan/amlodipine single-pill combination angiotensin receptor blocker/calcium channel blocker free-combination therapy. *American Society of Hypertension (ASH) 28th Annual Scientific Meeting and Exposition*. San Francisco, CA: May 15-18, 2013.
190. Xie L, Spalding J, Baser O. Differences in test-related clinical and economic outcomes between patients who underwent single-photon emission computed tomography using regadenoson versus patients who underwent echocardiograms using dobutamine. *American Heart Association Quality of Care & Outcomes Research (AHA QCOR) 2013 Scientific Sessions*. Baltimore, MD: May 15-17, 2013.
191. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Assessing the clinical and economic burden of U.S. veteran ankylosing spondylitis patients. *American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting*. Washington D.C.: November 9-13, 2012.

192. Baser O, Wang L, Du J, Wang H, Xie L. Impact of Severity Index for Rheumatoid Arthritis on health care costs and utilizations in patients with rheumatoid arthritis. *American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting*. Washington D.C.: November 9-13, 2012.
193. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Determinants of total health care costs associated with rheumatoid arthritis prevalent cases in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
194. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Total health care costs associated with ankylosing spondylitis incident cases in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
195. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Determinants of total health care costs associated with ankylosing spondylitis prevalent cases in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
196. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Total health care costs associated with rheumatoid arthritis incident cases in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
197. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. Regional variation in angiogram use for patients who underwent coronary artery bypass graft surgery. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
198. Baser O, Burkan A, Baser E, Koselerli R, Ertugay E, Altinbas A. High cost patients for cardiac surgery and hospital quality in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
199. Akkoç N, Direskeneli H, Erdem H, Gül A, Kabasakal Y, Kiraz S, Durguner B, Baser O, Hamuryudan V. Indirect costs associated with ankylosing spondylitis in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
200. Baser O, Xie L, Huang A, Li L, Fritschel EK, Wang L. Assessing the survival rates and economic burden of prostate cancer in the U.S. veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
201. Supina D, Lewis-Beck C, McElroy S, Hodgkins P, Baser O. Health care resource utilization and costs for patients with anorexia nervosa, bulimia nervosa, and binge eating disorder. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
202. Memiş SA, Değer C, Marmaralı B, Paralı E, Sümer F, Karakeben K, Başer O. New pricing policies after initiation of the Health Transformation Programme in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
203. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Geographic variation associated with colorectal cancer prevalence in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.

204. Baser O, Wang L, Du J, Wang H, Xie L. Impact of Severity Index for Rheumatoid Arthritis on health care costs and utilizations in patients with rheumatoid arthritis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012. [FINALIST AWARD]
205. Hamuryudan V, Direskeneli H, Ertenli I, İnanç M, Karaslan Y, Oksel F, Özbek S, Pay S, Terzioğlu E, Durguner B, Baser O, Akkoç N. Indirect costs associated with rheumatoid arthritis in Turkey. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
206. Wang L, Xie L, Li L, Huang A, Wang H, Baser O. Visualizing treatment patterns of veteran patients with rheumatoid arthritis who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
207. Baser O, Wang L, Li L, Huang A, Wang H, Xie L. Application of data visualization tool: Treatment patterns of veteran patients with ankylosing spondylitis who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
208. Baser O, Wang L, Lewis-Beck C, Wang H, Li L, Xie L. Demographic and socioeconomic characteristics that affect selection of intravenous versus subcutaneous injection tumor necrosis factor inhibitors for rheumatoid arthritis patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012. [FINALIST AWARD]
209. Lewis-Beck C, Baser E, Baser O. An applied comparison of meta-analysis techniques using Bacille Calmette Guerin vaccine studies. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
210. Xie L, Wang L, Huang A, Li L, Fritschel EK, Baser O. Geographic variation trends in diabetes mellitus prevalence in the United States veteran population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
211. Xie L, Wei W, Pan C, Baser O. Real-world incidence of hypoglycemia and associated costs among insulin-glargine treated patients with type 2 diabetes mellitus (T2DM). *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
212. Baser E, Lewis-Beck C, Baser O. An Excel calculator tool to perform meta-analysis. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
213. Xie L, Baser O, Huang A, Li L, Fritschel EK, Wang L. Assessing the clinical and economic burden of U.S. veteran ankylosing spondylitis patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
214. Wang L, Baser O, Huang A, Li L, Fritschel EK, Xie L. Evaluation of the clinical and economic burden of the human immunodeficiency virus in U.S. veteran patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
215. Baser O, Wang L, Li T, Shu Z, Xie L. Prevalence and incidence rates of multiple sclerosis in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.

216. Xie L, Du J, Altınbas S, Baser O. Compare health care utilization and costs among menopausal women with different symptoms by linking women's registry and claims data. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
217. Xie L, Lewis-Beck C, Wang H, Altınbas S, Baser O. Demographic and clinical characteristics of menopausal women in the University of Michigan Women's Registry Database. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress*. Berlin, Germany: November 3-7, 2012.
218. Baser O, Zhou S, Wei W, Ling Z, Xie L, Levin P. Adding a third agent to two oral antidiabetic drugs (OADs): Real-world economic impact and effect of treatment persistence on clinical outcomes. *48th European Association for the Study of Diabetes (EASD) Annual Meeting*. Berlin, Germany: October 1-5, 2012.
219. Levin P, Wei W, Vlajnic A, Pan C, Xie L, Lin J, Baser O. Real-world practice pattern and outcomes of patients with type 2 diabetes (T2DM) initiating injectable therapy via insulin glargine disposable pen (GLA-P) or liraglutide (LIRA). *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.
220. Levin P, Wei W, Vlajnic A, Pan C, Xie L, Lin J, Baser O. Real-world outcomes of initiating injectable therapy with insulin glargine or liraglutide among patients with type 2 diabetes. *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.
221. Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Health outcomes of switching from vial to disposable pen among type 2 diabetes patients treated with insulin glargine. *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.
222. Xie L, Zhou S, Wei W, Lin J, Baser O, Levin P. Treatment patterns and A1C reduction after adding a 3rd agent to 2 oral antidiabetic drugs (OADs). *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.
223. Wei W, Pan C, Xie L, Baser O. Association of treatment persistence and adherence with real-world outcomes among insulin-treated patients with type 2 diabetes mellitus (T2DM). *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012. [Oral presentation]
224. Baser O, Miao R, Wei W, Xie L. Real world outcomes of adding rapid acting insulin vs. switching to analog premix insulin among patients with type 2 diabetes treated with insulin glargine. (Abstract) *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012. *Diabetes*. 2012;(suppl: 2455- PO).
225. Baser O, Tangirala K, Wei W, Xie L. Real-world outcomes of initiating glargine-based insulin treatment vs. analog premix insulin among patients with type 2 diabetes failing oral antidiabetes drugs. *American Diabetes Association (ADA) 72nd Scientific Sessions*. Philadelphia, PA: June 8-12, 2012.
226. Baser O, Wang L, Xie L, Du J, Wang H. Health care outcomes research: Effectiveness of a Severity Index for Rheumatoid Arthritis. *The European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology*. Berlin, Germany: June 6-9, 2012. [Abstract]
227. Baser O, Wang L, Xie L, Yuce H. Treatment pattern visualization of Medicare patients diagnosed with rheumatoid arthritis and initiating tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012.

228. Baser O, Wang L, Xie L, Du J, Wang H. Derivation of Severity Index for Rheumatoid Arthritis and its effect on health care outcomes. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
229. Baser O, Schmeichel-Mueller C, Ingham M. Using scatter plots, analysis of univariate relationship between confounders and outcomes among rheumatoid arthritis patients who initiated anti-tumor necrosis factors and subsequently switched or escalated. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
230. Baser O, Schmeichel-Mueller C, Ingham M. Analyzing the difference in health care costs of rheumatoid arthritis patients switching or dose escalating anti-TNF biologics using combined propensity score matching and multivariate regression model. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
231. Lewis-Beck C, Baser E, Baser O. A review and applied comparison of meta-analysis techniques. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
232. Baser O, Wang L, Xie L, Yuce H. Data visualization of treatment patterns of Medicare psoriatic arthritis patients who initiate tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
233. Miao R, Wei W, Xie L, Baser O. Does pen help when elderly patients with type 2 diabetes initiate insulin? A real world retrospective study of initiating insulin glargine via disposable pen vs. vial. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012. [Podium presentation]
234. Xie L, Joshi AV, Harnett J, Mardekian J, Schaaf D, Shah N, Baser O. Differences in health care utilization and associated costs between patients prescribed versus not prescribed opioids during an inpatient or emergency department visit. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
235. Baser O, Wang L, Xie L, Yuce H. Application of data visualization tool: Treatment patterns of Medicare patients with ankylosing spondylitis who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
236. Baser O, Liu X, Phatak H, Wang L, Mardekian J, Kawabata H, Petersel D, Hamilton M, Ramacciotti E. Venous thromboembolism prophylaxis and clinical consequences in hospitalized medically ill patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
237. Baser O, Wang L, Xie L, Yuce H. Treatment patterns of Medicare patients with ulcerative colitis initiating tumor necrosis factor therapy: Application of a data visualization tool. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.
238. Baser O, Wang L, Xie L, Yuce H. Visualizing treatment patterns of Medicare patients with Crohn's disease who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C: June 2-6, 2012.

239. Wang L, Wei W, Miao R, Xie L, Baser O. Real-world health care utilization, productivity and associated costs among employees with type 2 diabetes mellitus treated with insulin glargine or neutral protamine Hagedorn (NPH) insulin in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012.
240. Baser O, Xie L, Du J, Smith Y. Application of probabilistic linkage: Compare health care costs among menopausal women with different symptoms by linking women's registry and claims database. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
241. Xie L, Racketta J, Bushmakina A, Mirkin S, Trocio J, Baser O. Economic impact of breast pain and bleeding among women prescribed estrogen plus progestogen hormone therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, DC: June 2-6, 2012.
242. Baser O, Racketta J, Bushmakina A, Komm B, Trocio J, Xie L. Clinical and economic outcomes associated with early combined estrogen and progestogen hormone therapy for post-menopausal women. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012.
243. Wang L, Li L, Huang A, Baser O. Assessing the clinical and economic burden of veteran breast cancer patients in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012.
244. Wang L, Li L, Huang A, Baser O. Colorectal cancer patients in the veteran population: A health care cost and utilization analysis in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012.
245. Wang L, Li L, Huang A, Baser O. A descriptive analysis of ovarian cancer in veteran patients in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012.
246. Baser O, Wang L. Evaluation of the clinical and economic burden of the human immunodeficiency virus in veteran patients in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012.
247. Baser O, Wang L, Xie L, Yuce H. Using data visualization to illustrate treatment patterns of Medicare patients with diagnosis of psoriasis who initiated tumor necrosis factor therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012.
248. Abouzaid S, Lewis-Beck C, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis severity and quality of life, work productivity, and activity impairment among patients with moderate to severe psoriasis using structural equation modeling. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting*. Washington, D.C.: June 2-6, 2012. [FINALIST AWARD]
249. Wang L, Joshi AV, Schaaf D, Mardekian J, Baser O. Prevalence of diagnosed opioid abuse in the national veteran's health administration (VA) population. *American Pain Society 31st Annual Scientific Meeting*. Honolulu, HI: May 16-19, 2012.

250. Baser O, Joshi AV, Schaaf D, Mardekian J, Wang L. Economic burden of diagnosed opioid abuse in the national veteran's health administration (VA) population. *American Pain Society 31st Annual Scientific Meeting*. Honolulu, HI: May 16-19, 2012.
251. Lin J, Xie L, Wei W, Zhou S, Miao R, Pan C, Baser O. An empirical approach to measure and predict treatment persistence among insulin-glargine treated patients with type 2 diabetes. *AMCP 24th Annual Meeting & Expo*. San Francisco, CA: April 18-20, 2012.
252. Baser O, Weis AJ, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid dependence treatments. *AMCP 24th Annual Meeting & Expo*. San Francisco, CA: April 18-20, 2012.
253. Wang L, Xie L, Du J, Li L, Huang A, Li T, Shu Z, Baser O. Claims-based Severity Index for Rheumatoid Arthritis from health care claims data. *China Outcomes Research & Evidence Based Medicine (CORE) Summit*. Shanghai, China: March 30-31, 2012.
254. Baser O, Wang L, Xie L. Health care cost comparisons between alcohol or opioid-dependent patients who were treated with medication and those who were not. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
255. Baser O, Wang L. Evaluation of the prophylaxis patterns and 90-day outcome events in hospitalized medically-ill patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
256. Baser O, Wang L. Thromboprophylaxis use and venous thromboembolism, major and minor bleeding event analysis in hospitalized medically ill patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
257. Baser O, Wang L. Geographic variation trends in critical limb ischemia prevalence in the United States. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
258. Baser O, Wang L. Analysis of transient ischemic attack-related clinical outcomes, health care utilization and cost burden of patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
259. Baser O, Wang L. Clinical outcomes and costs associated with stroke in patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
260. Baser O, Wang L. Clinical and economic burden of major bleeding in abdominal surgery patients. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
261. Xie L, Baser E, Baser O. Treatment patterns and associated clinical and economic outcomes of women treated with hormone therapy. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
262. Xie L, Baser E, Wang L, Baser O. Gastroesophageal reflux disease patients who switched from a branded proton pump inhibitor to a generic one and vice versa: A cost comparison. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011. [FINALIST RESEARCH AWARD]

263. Wei W, Baser O, Du J, Xie L, Pan C. Real-world outcomes of initiating two different basal insulin therapies via disposable pens among patients with type 2 diabetes in US employer-sponsored health plans. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
264. Wang L, Xie L, Baser O. Assessment of drug adherence for type 2 diabetes patients using vial or pen form insulin: A method to adjust the traditional medication possession ratio. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress*. Madrid, Spain: November 5-9, 2011.
265. Baser O, Mody R, Morlock R, Baser E, Xie L. Comparison of daily average consumption between different proton pump inhibitors in patients with gastroesophageal reflux disease. *The American College of Gastroenterology (ACG) Annual Scientific Meeting*. Washington, DC: October 28 - November 2, 2011.
266. Baser O, Mody R, Morlock R, Xie L, Baser E. Characteristics of patients who switched from twice daily (BID) protein pump inhibitors (PPI)s to once-daily (QD) dexlansoprazole or QD other PPIs. *American College of Nurse Practitioners (ACNP) 2011 Clinical Conference*. Denver, CO: October 5-9, 2011.
267. Baser O, Xie L, Wei W, Chunshen P, Du J. Real-world clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine disposable pen vs. insulin detemir disposable pen in a US managed care setting. *European Association for the Study of Diabetes (EASD) 47th Annual Meeting*. Lisbon, Portugal: September 12-16, 2011.
268. Baser O, Wei W, Xie L, Baser E. Clinical and economic outcomes in patients with type two diabetes initiating insulin glargine using disposable pen vs. exenatide. *European Association for the Study of Diabetes (EASD) 47th Annual Meeting*. Lisbon, Portugal: September 12-16, 2011.
269. Verpillat P, Baser O, Wang L. How real-life data analysis could highlight ethnic inequalities in access to health care: Example of critical limb ischemia in the U.S. Medicare population. *27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management*. Chicago, IL: August 14-17, 2011. 20 (Suppl 1):S146-S147(337).
270. Levin P, Wei W, Wang L, Damon D, Baser O. Clinical characteristics, outcomes and treatment persistence in patients with T2DM adding insulin glargine to exenatide or exenatide to insulin glargine in a US Managed Care setting. *American Diabetes Association (ADA) 71st Scientific Session*. San Diego, CA: June 24-28, 2011.
271. Baser O, Verpillat P, Wang L. Prevalence, incidence and outcomes of critical limb ischemia in the US Medicare population. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
272. Baser O, Du J, Xie L, Baser E. Comparison of major bleeding related mortality, health care utilization and cost of patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
273. Baser O, Xie L, Du J, Wang L. Analysis of treatment patterns and costs for venous thromboembolism, major and minor bleeding events in hospitalized medically ill patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
274. Baser O, Xie L, Yuce H, Du J, Wang L. Prophylaxis use and 90-day costs for venous thromboembolism, major and minor bleeding event analysis in hospitalized medically ill patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.

275. Wang L, Dysinger A, Du J, Xie L, Baser O. Treatment patterns, clinical and economic burden of venous thromboembolism in abdominal surgery patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
276. Wang L, Xie L, Baser O. Analysis of myocardial infarction related clinical outcomes, health care utilization and costs of patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
277. Baser O, Xie L, Wang L, Du J. Comparison of propensity score matching and instrumental variable methods when estimating health care costs of rheumatoid arthritis patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
278. Baser O, Xie L. Applying the stratified propensity score matching method when estimating healthcare costs of rheumatoid arthritis patients. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
279. Baser O, Wang L, Yuce H, Xie L, Dysinger A. Differences in outcomes measures of diabetes patients using an insulin device and a conventional human insulin vial/syringe. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
280. Baser O. Excess payments from Medicare for inpatient surgery. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
281. Baser O. Measuring drug therapy guidelines on outcomes: A tutorial. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
282. Baser O, Wang L, Xie L. Comparison of health care costs and utilizations between patients who were treated with pharmacological and non-pharmacological substance medications for alcohol dependency. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
283. Baser O, Wang L, Xie L. Comparison of health care costs and utilizations between patients who were treated with and without medication for opioid dependency. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
284. Xie L, Baser E, Wang L, Baser O. Comparison of health care utilizations between patients with Gastroesophageal Reflux Disease who switched from a branded proton pump inhibitor to a generic proton pump inhibitor and vice versa. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th International Meeting*. Baltimore, MD: May 21-25, 2011.
285. Baser O, Mody R, Morlock R, Xie L, Baser E. Characteristics of patients who switched from twice daily (BID) proton pump inhibitors (PPI)s to once-daily (QD) Dexlansoprazole or QD other PPIs. *2011 Digestive Disease Week*. Chicago, IL: May 7-10, 2011.
286. Mueller, SC, Baser O, Bolge SC, Ingham M. Healthcare costs of patients switching or dosing escalating anti-tumor necrosis factor therapy. *The Academy of Managed Care Pharmacy (AMCP) 23rd Annual Meeting & Showcase*. Minneapolis, Minnesota: April 27-29, 2011.
287. Baser O, Sengupta N, Wang L. Risk of venous thromboembolism and prophylaxis use in hospitalized medically-ill US patients up to 180 days post-hospital discharge. *The Academy of Managed Care Pharmacy (AMCP) 23rd Annual Meeting & Showcase*. Minneapolis, Minnesota: April 27-29, 2011.

288. Baser O, Baser E, Wei W. Clinical and economic outcomes in patients with type 2 diabetes initiating insulin glargine using disposable pen versus exenatide. *The Academy of Managed Care Pharmacy (AMCP) 23rd Annual Meeting & Showcase*. Minneapolis, Minnesota: April 27-29, 2011
289. Baser O. Survival, health care utilization and cost after recurrence among patients with triple breast cancer in a U.S. managed care setting. *33rd Annual San Antonio Breast Cancer Symposium*. San Antonio, Texas: December 8-12, 2010.
290. Baser O. Survival, health care utilization of patients with triple negative breast cancer in a U.S. managed care setting. *33rd Annual San Antonio Breast Cancer Symposium*. San Antonio, Texas: December 8-12, 2010.
291. Baser O, Dysinger A, Baser E, Yuce H. Use of propensity score matching, standard regression analysis and instrumental variable method in outcomes research studies: A comparative analysis. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
292. Baser O, Akin C. Claims-based severity index for rheumatoid arthritis from healthcare claims data. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
293. Baser O, Yuce H. Extending fixed effect models to censored cost data. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
294. Baser O, Wang L, Xie L. Determinants of TNF inhibitor dose escalation in patients with rheumatoid arthritis. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
295. Wang L, Dysinger A, Baser O. Estimation of adverse events in 3 months after venous thromboembolism event for Medicare patients who underwent hip fracture surgery. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
296. Baser O. Creating an efficient hospital payment system. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
297. Baser O, Akin C, Wang L, Dysinger A. Hospital quality index and its use on rates of venous thromboembolism. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010. [FINALIST RESEARCH AWARD]
298. Wang L, Dysinger A, Baser O. Comparison of adverse events of Medicare patients who underwent knee replacement surgery and experienced venous thromboembolism in versus no venous thromboembolism. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
299. Baser O, Wang L, Xie L. Clinical and cost outcomes of venous thromboembolism in patients who underwent major orthopedic surgery. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
300. Wang L, Baser O. Comparison of mortality, health care utility and cost of patients with warfarin treatment for non-valvular atrial fibrillation versus patients with other treatment. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.

301. Wang L, Baser O. Estimation of stroke-related adverse events, health care utility and cost of patients with non-valvular atrial fibrillation. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
302. Baser O, Wang L, Dysinger A. Analysis of anticoagulation bridging therapy in orthopedic patients: Real-world analysis. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
303. Baser O, Wang L, Xie L, Dysinger A, Yuce H, Baser E. Deriving doctors' prescribing patterns from health care claims: An instrumental variable analysis. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual European Congress*. Prague, Czech Republic: November 2010.
304. Mueller CS, Baser O, Bolge SC, et al. Clinical characteristics and health care costs of rheumatoid arthritis patients who switch anti-TNF agents. *Academy of Managed Care Pharmacy's Educational Conference*. St Louis, Missouri: October 2010.
305. Baser O, Akin C. Deriving severity index for rheumatoid arthritis from healthcare claims data. *Annual European Congress of Rheumatology*. Rome, Italy: June 2010.
306. Baser O. Deriving doctors' prescribing patterns from claims data: An application to TNF and non-TNF biologics. *Annual European Congress of Rheumatology*. Rome, Italy: June 2010.
307. Baser O, Supina D, Sengupta N, et al. Cost of VTE events to Medicare patients undergoing TKA/THA according to discharge status. *National Association of Orthopedic Nurses Meeting*. Seattle, Washington: May 15-19, 2010.
308. Baser O, Wang L, Sengupta N, et al. Cost of venous thromboembolism events according to discharge status of Medicare patients after major orthopaedic surgery. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
309. Baser O, Yuce H. A method to increase sample size by removing the continuous enrollment requirement. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
310. Baser O, Yuce H. Time series analysis to examine the effect of guidelines. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
311. Baser O, Gust C. Deriving doctors' prescribing patterns from claims data: An application to TNF and non-TNF biologics. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
312. Baser O, Gust C, Akin C. Deriving severity index for rheumatoid arthritis from health care claims data. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
313. Baser O, Wang L, Gust C, Dysinger A. Examination of doctors' practice and prescribing patterns toward SSRI and SNRI. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
314. Wang L, Baser O. Analysis of "bridging therapy" in orthopedic patients in a U.S. health plan. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.

315. Baser O, Dysinger A, Baser E. Comparing risk-adjustment models: Propensity score matching, standard regression analysis and instrumental variable approach. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010. [FINALIST RESEARCH AWARD]
316. Baser O, Yuce H. Modeling transformed health care costs with unknown heteroskedasticity. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
317. Wang L, Baser O. Difference in outcomes measures of patients with valvular and non-valvular atrial fibrillation. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
318. Baser O, Yuce H, Wang L. Rare event bias in retrospective analysis of outcomes measures. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
319. Wang L, Baser O. Adverse event analysis for Medicare patients who underwent hip fracture surgery and suffered venous thromboembolism. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
320. Wang L, Dysinger AH, Baser O. Comparison of mortality, re-hospitalization and bleeding rates of Medicare patients who underwent knee replacement surgery. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
321. Wang L, Dysinger AH, Baser O. Estimation of adverse events related with Medicare patients who underwent hip fracture surgery and suffered VTS versus no VTE. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
322. Baser O, Akin C, Wang L, Dysinger AH. Relationship between venous thromboembolism and hospital quality. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
323. Wang L, Gust C, Baser O. Deriving doctors' prescribing patterns from claims data: An application to anticoagulant use with non-valvular atrial fibrillation. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
324. Baser O, Wang L, Supina D, Sengupta N. Cost of VTE events for Medicare patients undergoing major orthopedic surgeries according to discharge status. *15th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Atlanta, Georgia: May 2010.
325. Baser O, Dysinger AH. Comparison of risk adjustment models in outcomes research. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.
326. Baser O, Dysinger AH. Controlling for unobservable bias: Is the cure worse than the disease? *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.
327. Baser O, Wang L. Creating national weights for private insurance database. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.

328. Baser O, Wang L. Forecasting the number of diabetic patients in the United States in 2050. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.
329. Baser O. Relationship between cost and hospital quality. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 12th Annual European Congress*. Paris, France: October 2009.
330. Baser O, Supina D, Sengupta N, Wang L. Incidence and burden of “never events” for Medicare patients undergoing total hip or total knee replacement surgery. *XXII Congress of International Society on Thrombosis and Homeostasis*. Boston, Massachusetts: July 2009.
331. Baser O, Supina D, Sengupta N, et al. Impact of venous thromboembolism on U.S. Medicare patients undergoing total hip and total knee replacement surgery. *XXII Congress International Society on Thrombosis and Homeostasis*. Boston, MA: July 11-16, 2009.
332. Baser O, Supina D, Sengupta N, et al. Incidence and burden of ‘never events’ for Medicare patients undergoing total hip or total knee replacement surgery. *American Society of Health System Pharmacist Summer Meeting*. Chicago, IL: June 14-17, 2009.
333. Baser O, Wang L. Forecasting the number of diabetic patients in the United States through 2025. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
334. Baser O, Dysinger A. Instrumental variable approach in outcomes research. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
335. Baser O, Wang L, Gust C, Dysinger A. Socioeconomic status and cost of care in the elderly undergoing major orthopedic surgery. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
336. Baser O, Dysinger A. Too much ado about instrumental variable approach: Is the cure worse than the disease? *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
337. Baser O, Gust C, Akin C. Comparing and validating different types of propensity score matching techniques. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
338. Baser O, Yuce H, Gust C. Extending random effect models to censored cost data. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
339. Baser O. Creating a quality index to rank hospitals. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
340. Crown WH, Baser O. Short course: Retrospective database analysis. *14th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Orlando, Florida: May 2009.
341. Baser O, Supina D, Sengupta N, et al. Burden of VTE ‘never events’ for Medicare patients undergoing total hip or total knee replacement surgery. *Mid America Orthopedic Association Meeting*. Lost Pines, Texas: April 21-25, 2009.

342. Morrato EH, Newcomer JW, Kamat S, Baser O, *et al.* Impact of the atypical antipsychotic FDA warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. *New Clinical Drug Evaluation Unit CME Poster Session*. BEST RESEARCH POSTER. CME Institute, Physicians Postgraduate Press, Inc. *J Clin Psy.* October 2008.
343. Baser O. Performance of your 5-star hospitals. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 11th Annual European Congress*. Athens, Greece: November 2008.
344. Morrato E, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening before and after the ADA consensus statement on antipsychotic drugs and risk of diabetes and dyslipidemia. *International Society for Pharmacoepidemiology and Therapeutic Risk Management*. August 2008.
345. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening before and after the ADA consensus statement on antipsychotic drugs and risk of diabetes and dyslipidemia. *American Diabetes Association's 68th Scientific Sessions*. San Francisco, CA: June 6-10, 2008.
346. Morrato EH, Newcomer JW, Kamat S, Baser O, *et al.* Impact of the atypical antipsychotic FDA warning on risk of hyperglycemia and diabetes and metabolic monitoring practices. *48th Annual NCDEU Meeting, co-sponsored by the National Institute of Mental Health (NIMH) and the American Society of Clinical Psychopharmacology (ASCP)*. Phoenix, Arizona: May 27-30, 2008.
347. Baser O, Gust C. Sensitivity analysis for propensity score matching. *13th Annual Meeting of the International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Toronto, Canada: May 2008.
348. Baser O, Poling L, Schaeffer J, Maguire J, Mummidi V. Creating national weights for a large-scale, patient longitudinal database. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, Canada: May 2008.
349. Baser O, Wang L. A model to examine the effect of guidelines on outcomes research. *International Society for Pharmacoeconomic and Outcomes Research 13th Annual Meeting*. Toronto, Canada: May 2008.
350. Baser O, Yuce H. Controlling for potential censoring bias on dependent variables. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, Canada: May 2008.
351. Baser O, Yuce H. Inverse probability weighted random effect models for estimation of censored outcomes variables. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, Canada: May 2008.
352. Baser O. Medicare outlier payments for coronary artery bypass grafting. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, Canada: May 2008.
353. Baser O. Relationship between quality of care and excessive cost for Medicare patients undergoing lower extremity bypass surgery. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 13th Annual Meeting*. Toronto, Canada: May 2008.
354. Englesbe J, Fan Z, Baser O, Birkmeyer JD, Dimick JB. Developing better measures of transplant center performance. *American Transplant Congress*. May 2008.
355. Morrato EH, Newcomer JW, Kamat S, Baser O, *et al.* Trends in annual metabolic screening for patients taking second-generation antipsychotic medications. *American Psychiatric Association (APA) 161st Annual Meeting*. Washington, D.C.: May 3-8, 2008.

356. Dimick JB, Baser O, Birkmeyer JD. Variations in surgical mortality rates: Differences in quality or just statistical noise? Abstract published in *J Surg Res*. February 2008.
357. Morrato E, Newcomer JW, Siddhesh K, Baser O, *et al.* Metabolic screening before and after the ADA consensus statement on antipsychotic drugs and risk of diabetes and dyslipidemia. *American Diabetic Association (ADA) 68th Scientific Sessions*. San Francisco, California: 2008.
358. Foley K, Kalsekar A, Baser O, Walsh JK. Health care costs of patients with insomnia: How much does the health plan and patient pay. *21st Annual Meeting of the Associated Professional Sleep Societies*. Minneapolis, Minnesota: June 9-14, 2007.
359. Baser O, Foley K. An application of latent class cluster analysis in outcomes research: Identifying high cost insomnia patients. *19th Annual Research Meeting of Academy Health*. Orlando, Florida: June 3-5, 2007.
360. Baser O. Using propensity score matching techniques for average treatment effects: Application to triptan use. *19th Annual Research Meeting of Academy Health*. Orlando, Florida: June 3-5, 2007.
361. Baser O. Is cure worse than the disease? *12th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research*. Washington, D.C.: May 19-23, 2007.
362. Curtis J, Barr C, Baser O, Amonkar M, Saag K. Reduced osteoporosis-related expenditures, overall health care expenditures and health resource utilization observed for woman adherent to bisphosphonate therapy. *American College of Rheumatology (ACR) Annual Scientific Meeting*. Washington, D.C.: November 10-15, 2006.
363. Baser O. Continuous enrollment requirement: Do we really need it? *Inaugural Conference of the American Society of Health Economists*. Madison, Wisconsin: June 4-7, 2006.
364. Baser O, Stephenson J. The estimation power of alternative comorbidity indexes. *18th Annual Research Meeting of Academy Health*. Seattle, Washington: June 25-27, 2006.
365. Baser O. A method to remove continuous enrollment requirement from pharmacoecconomical studies. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
366. Baser O, Stephenson J. The estimation power of alternative comorbidity indexes. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
367. Baser O. Controlling selection bias on continuous variables. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
368. Baser O. Performance of bootstrapping in discrete choice models. *18th Annual Research Meeting of Academy Health*. Seattle, Washington: June 25-27, 2006.
369. Baser O. Propensity score matching with more than two categories. *18th Annual Research Meeting of Academy Health*. Seattle, Washington: June 25-27, 2006.
370. Krishnan AA, Foley K, Montejano L, Baser O, Long S, Walsh JK. Insomnia: Prevalence, comorbidities, costs in a treated insured population. *20th Anniversary Meeting of the Associated Professional Sleep Societies*. Salt Lake City, Utah: June 17-22, 2006.

Onur Başer
Sayfa 41

371. Baser O. Propensity score modeling with limited overlap. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
372. Baser O. Failure of regression adjustment against propensity score matching. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
373. Baser O. One solution to three problems. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
374. Baser O. Performance of bootstrapping in discrete choice models. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
375. Baser O. Propensity score matching with more than two categories. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
376. Foster S, Foley K, Baser O, Meadows E, Long S. Trends in the clinical management of fragile fracture before and after the new HEDIS osteoporosis management measures in a Medicare population. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006.
377. Curtice TG, Long SR, Baser O, Montejano LB, Lobo F. Economic burden of restless legs syndrome in a privately-insured population. *11th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Philadelphia, Pennsylvania: May 20-24, 2006. [FINALIST RESEARCH AWARD]
378. Gibson TB, Mark T, Axeslsen K, Mackell J, King H, Baser O, McGuigan K. The effects of statin copayments and statin adherence on medical care utilization and expenditures. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 11th Annual Meeting*. Philadelphia, Pennsylvania: May 20-24, 2006. [BEST CONTRIBUTED RESEARCH AWARD]
379. Montejano LB, Long SR, Baser O, Lobo F, Curtice TG. Restless legs syndrome: Identification of treated patients in a large claims data base. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 11th Annual Meeting*. Philadelphia, Pennsylvania: May 20-24, 2006.
380. Baser O. Propensity score matching and multivariate analysis: Complement or substitute? *18th Annual Meeting of Academy of Managed Care Pharmacy*. Seattle, Washington: April 5-8, 2006.
381. Gibson TB, Mark T, Axeslsen K, Mackell J, King H, Baser O, McGuigan K. The effects of statin copayments and statin adherence on medical care utilization and expenditures. *American College of Cardiology 55th Annual Scientific Session*. Atlanta, Georgia: March 11-14, 2006.
382. Baser O. Too much ado about propensity score matching? *6th International Health Policy Conference*. Boston, Massachusetts: October 28-30, 2005.
383. Ozminkowski R, Goetzel R, Shechter D, Baser O, Lapin P. Predictors of preventive service use among Medicare beneficiaries. *Academy Health Annual Research Meeting*. Boston, Massachusetts: June 26-28, 2005 and *3rd National Prevention Summit*. Washington D.C.: October 24-25, 2005.
384. Ozminkowski R, Goetzel R, Shechter D, Baser O, Lapin P. Predictors of preventive service use among Medicare beneficiaries. *Academy Health Annual Research Meeting*. Boston, Massachusetts: June 26-28, 2005.
385. Baser O, Long S. Which one is logical? Logit or rare-event logit. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May 15-18, 2005.

386. Baser O. Choosing among different types of matching techniques. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May15-18, 2005.
387. Baser O. Retransformation of estimated log-transformed costs when the errors present heteroskedasticity. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May15-18, 2005.
388. Baser O. Estimation of censored medical count data. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May15-18, 2005.
389. Long S, Robinson R, Chang S, Able S, Baser O, Swindle R. Appropriateness and variation in drug utilization across patients with depression. *10th Annual Meeting of International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May 15-18, 2005.
390. Baser O. A test to determine possible selection bias due to censoring in medical cost estimation. *25th Annual American Economic Association Meeting*. Philadelphia, Pennsylvania: January 7-9, 2005.
391. Song X, Marder W, Baser O, Houchens B, Conklin J, Bradley R. Can health care claims data improve the estimation of the medical CPI? *Conference on Research in Income and Wealth, National Bureau of Economic Research*. Vancouver, Canada: June 28-29, 2004.
392. Hawkins K, Grossman P, Lucinda O, Ozminkowski R, Baser O. Examination of total health care expenditures for patients on long acting opioid medications for the treatment of chronic pain in a Medicaid population. *Academy Health Annual Research*. San Diego, Virginia: June 6-8, 2004.
393. Baser O, Given C. Weight or not to weight? *1st Conference of the Canadian Association for Health Services and Policy Research*. Montreal, Canada: May 25-28, 2004.
394. Baser O, Bradley CJ, Gardiner C, Given C. Testing and correcting for non-random selection bias due to censoring: An application to medical costs. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May16-19, 2004.
395. Baser O, Crown W. Choosing among different kinds of bootstrapping methods. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May16-19, 2004. [FINALIST RESEARCH AWARD]
396. Baser O, Bradley CJ, Gardiner C, Given C. Censored medical cost estimation. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May16-19, 2004.
397. Baser O, Gardiner J, Bradley C, Yuce H, Given C. Panel analysis of censored medical cost. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May16-19, 2004.
398. Baser O, Given C. Weight or not to weight? *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May16-19, 2004.
399. Hawkins K, Grossman P, Lucinda O, Ozminkowski R, Baser O. Examination of total health care expenditures for patients on long acting opioid medications for the treatment of chronic pain in a Medicaid population. *International Society for Pharmacoeconomic and Outcomes Research (ISPOR)*. Arlington, Virginia: May16-19, 2004.

400. Hawkins K, Grossman P, Lucinda O, Ozminkowski R, Baser O. Examination of total health care expenditures for patients on long acting opioid medications for the treatment of chronic pain in a Medicaid population. *AMCP (Academy of Managed Care Pharmacy) 16th Annual Conference*. San Francisco, California: March 31-April 3, 2004.
401. Ozminkowski JR, Baser O, Azzolini J, Fox K. Identifying high-cost asthma patients. *DATIA (Drug Alcohol Testing Industry Association) 2003 Annual Conference*. Washington D.C.: January 4, 2004.
402. Kozma C, Luella E, Long S, Greenspan A, Mahmoud R, Baser O. Absence of increased relative stroke risk in elderly dementia patients treated with risperidone versus other antipsychotic. *Annual Meeting of the International College of Geriatric Psychoneuropharmacology*. San Juan, Puerto Rico: December 12-14, 2003.
403. Baser O, Bradley CJ, Gardiner C, Given C. Testing and correcting for non-random selection bias due to censoring: An application to medical costs. *18th Annual Meeting of Society of Medical Decision Making*. Chicago, Illinois: October 19, 2003.
404. Ozminkowski JR, Baser O, Azzolini J, Fox K. Do you know who your high-cost asthma patient will be next year? *5th Annual Meeting of Disease Management Association of America*. Chicago, Illinois: October 12, 2003.
405. Baser O, Gardiner J, Bradley C, Yuce H, Given C. Longitudinal analysis of censored medical cost. *Econometric Society 24th North America Meeting*. Chicago, Illinois: June 27, 2003.
406. Baser O, Bradley C, Gardiner J, Given C. Estimation from censored medical cost. *4th World Congress, International Health Economics Association*. San Francisco, California: June 18, 2003.
407. Crown W, Berndt E, Baser O, Finkelstein S, Witt W, Haver K. Benefit plan design and prescription drug utilization among asthmatics: Do patient co-payments matter? *International Health Economics Association*. San Francisco, California: June 14, 2003.
408. Crown B, Baser O, Berndt E. Is propensity score an inferior version of instrumental variables? *International Health Economics Association*. San Francisco, California: June 14, 2003.
409. Bradley C, Given C, Baser O, Gardiner J. Initial surgery determines subsequent costs of breast cancer care. *Society for Medical Decision Making*. Baltimore, Maryland: October 21, 2002.
410. Baser O, Bradley C, Gardiner J, Given C. Estimation from censored medical cost. *24th Australian Conference of Health Economists*. Sydney, Australia: June 2002.
411. Baser O, Given C. Full parametric estimation of censored medical cost. *24th Australian Conference of Health Economists*. Sydney, Australia: June 2002.
412. Baser O, Pema E. Academic publications - Their reward, life-cycle profile, and depreciation over time: Evidence for academic economists in Midwestern universities. *Midwest Economic Association, Annual Meeting*. March 2002.
413. Baser O, Pema E. The longitudinal analysis of economics faculty salaries. *Red Cedar Spring Graduate Student Meetings*. Michigan State University, Spring 1999.

PATENTLİ ALGORİTMALAR

ProbChoice™
NatWeight™
SIFRA®
CompQual™

HÜKÜMET DESTEKLİ PROJELER

- UM-MICHR Grant (Baser, PI)** 9/1/07 – 8/30/08
Measuring the cost of surgical complications \$35,750 0 CM
Goal: To develop methods for measuring the costs of perioperative complications and the costs of downstream complications. To identify the types of complications associated with greatest excess costs.
- National Institute of Health R21 (Brahmajee, PI, Baser, Co-I)** 11/01/08 – 11/01/11
Carotid angioplasty and stenting in the elderly \$418,000 1.20 CM
Goal: To examine the dissemination and use of carotid angioplasty and stenting (CAS) in older adults.
- National Institute of Health R21 (Hollenbeck, PI, Baser, Co-I)** 4/1/09 – 3/31/11
Understanding the use and effectiveness of medical therapy for acute renal colic \$275,000 2.40 CM
Goals: To identify barriers to the use of medical expulsive therapy for urolithiasis. To quantify the extent to which medical expulsive therapy for urolithiasis obviates the need for surgery in clinical practice.
- Health and Human Services, Department of Health Care Research (Birkmeyer, PI, Baser O, Co-I)** 04/01/2010 - 01/31/2013
Quality return on investment for quality improvement in collaborative surgery \$879,535
Goal: To examine the profit associated with quality improvement in surgery among Medicare patients.
- Optimizing prophylaxis against venous thromboembolism (VTE) in bariatric surgery (Birkmeyer PI, Baser O Co-I)** 04/01/2010 - 01/31/2013
\$682,202
Goal: To examine VTE prophylaxis use and its association with VTE risk reduction and hospital readmission among surgery patients.
- National Institute of Health R21 (Brahmajee, PI, Baser, Co-I)** NOA Pending
Effect of CTA on invasive cardiac procedures \$1,838,536 1.20 CM
Goal: To assess how the adoption of cardiac CTA has affected population-based rates of invasive cardiac procedures like cardiac catheterization and coronary revascularizations, and how it has impacted the downstream utilization of these invasive cardiac procedures in patients undergoing cardiac CTA relative to traditional stress tests.
- National Institute of Health R21 (Wang, PI, Baser, Co-I)** NOA Pending
Understanding disparities in treatment with poor prognosis cancers \$627,658 1.20 CM
Goal: Using national Medicare data, the project will “deconstruct” variations in the intensity of care for poor prognosis cancers, identify the main determinants of aggressive treatment, and explore the relationship between intensity and outcomes.

HÜKÜMET DESTEKLİ PROJELER (Devamı)

NIA P01 (Birkmeyer, PI, Baser, Co-I)

Understanding and improving the efficiency for surgical care

NOA Pending
\$600,000 1.80 CM

Goal: To explore the major determinant of efficiency for general medical care or physician groups and hospitals. To examine the impact of efficiency technology diffusion in the elderly, focusing specifically on cardiac services. To explore the causes of racial, ethnic, and income-based disparities in quality and resource use and aim to develop hospital-level “report cards” characterizing disparities in treatment patterns both across and within hospitals.

National Institute of Health R01 (Chung, PI, Baser, Co-I)

Epidemiology in the use of biologics for the Medicare rheumatoid population

NOA Pending
\$2,400,212

Goal: To examine the medical and surgical treatment of rheumatology arthritis patients in the US elderly population by analyzing Medicare claims data.

ÜYELİKLER

American Economic Association

International Health Economics Association

International Society for Pharmacoeconomic and Outcomes Research

Econometric Society

Society of Medical Decision Making

HAKEMLİKLER

American Journal of Cardiovascular Drugs

Health Economics

Journal of Health Economics

Value in Health

Journal of American Health Promotion

Health Services and Outcomes Research

Managed Care Pharmacy

Health Services Research

Journal of Medical Economics

REFERANSLAR

1. Akin, Cem, MD, PhD, Associate Professor, Internal Medicine, Brigham & Women’s Hospital, Boston, MA.
2. Crown, William H, PhD, President, OptumInsight, A United Health Company, Boston, MA.
3. Wooldridge, Jeffrey, PhD, Distinguished Professor, Economics, Department of Economics, Michigan State University, E. Lansing, MI.
4. Gardiner Joseph, PhD. Distinguished Professor, Statistics, Department of Epidemiology, Michigan State University, E. Lansing, MI.